Multiple sclerosis: neuroimmunology …

Anthony T Reder MD

Neuroimmunology

Updated 11.15.2025
Released 10.23.2014
Expires For CME 11.15.2028

Multiple sclerosis: neuroimmunology

Author: Anthony T Reder MD

See Contributor Disclosures

Cite this article

Multiple sclerosis: neuroimmunology

In This Article

Quick Link

Introduction

Overview

This is a comprehensive overview of immunology, immunopathology, and environmental pressures in multiple sclerosis. It complements other articles on the complex clinical characteristics and therapy of this disease.

Key points

	• Multiple sclerosis is caused by immune attack against brain cells.
	• The primary damage is from demyelination and destruction of oligodendroglia, but axons and neurons are also destroyed.
	• There is no known antigen or gene that causes multiple sclerosis, nor a spontaneous or induced match in animals.
	• Before any therapy, (1) immune control is reduced, leading to inflammation, and (2) interferon-alpha/beta levels in serum and responses to interferon are subnormal in multiple sclerosis.
	• Cortical lesions are difficult to see on MRI, but the damage affects cognition and many CNS functions.
	• Relapsing and progressive forms differ in gene regulation, immunity, and clinical course.
	• This article includes sections on etiology, pathogenesis, and epidemiology.

Etiology

There is an "autoimmune" attack against myelin and myelin-forming cells in the brain and spinal cord, but multiple sclerosis is not a typical autoimmune disease. There is no proven target antigen, including the myelin proteins that generate experimental allergic encephalomyelitis (EAE), an antigen-induced animal model. Multiple sclerosis does not arise spontaneously in wild mice or any other animals and is an exclusively human disease. There are surprisingly few links to other autoimmune diseases, except weak associations with inflammatory bowel disease (Crohn disease and ulcerative colitis) and thyroid disease. Down syndrome and systemic lupus erythematosus are underrepresented in multiple sclerosis populations and are linked to excessive responses to type I interferons. Conversely, in untreated multiple sclerosis, IFN-alpha and -beta levels and response to these type I IFNs are subnormal (143; 92). In this “Goldilocks phenomenon, interferon levels have to be just right for immune control. Some HLA types are associated with multiple sclerosis, but the mechanism for the connection is unclear. Immune disruption in multiple sclerosis may begin with an inciting event in the periphery or in the central nervous system, followed by intermittent or progressive immune attacks against the brain and spinal cord.

Specific antigenic targets and possible biomarkers for inflammation in multiple sclerosis. Brain proteins could trigger antigen-specific responses or modify immune reactivity over time. "Epitope spreading" to recognition of different, but related, antigens is seen in experimental allergic encephalomyelitis. In contrast, after monophasic postinfectious encephalomyelitis, there is epitope contraction and immune control that prevents a second attack. Candidate but unproven CNS antigen targets and disease modifiers include the following:

	• Proteins from infectious agents (viruses, chlamydia) could cross-react with immunologically similar brain antigens (“molecular mimicry”) or could be directly destructive (eg, staphylococcal myelinotoxic R3.89 antigen and Clostridium perfringens epsilon toxin).
	• Proteins from immune cells (recombinant signal binding protein for immunoglobulin kappa J region [RBP], nucleic acids).
	• Proteins from neurons (synapsin).
	• Myelin components (eg, myelin oligodendrocyte glycoprotein, myelin basic protein, proteolipid protein, and myelin-associated glycoprotein) and glycolipids (ganglioside GD1a, phosphatidyl-serine, phosphatidyl-choline). T cells that recognize myelin oligodendrocyte glycoprotein in mice often recognize neurofilament medium protein. Antibodies to MOG may also cross react with Epstein-Barr virus nuclear antigen. Heat shock protein-65 (HSP65) is highly conserved between bacteria and man, and it is cross-reactive with the myelin antigen, cyclic nucleotide phosphohydrolase (33).
	• Proteins from glia: Oligodendroglia – (2’,3’ cyclic nucleotide 3’ phosphodiesterase, alphaB-crystallin, KIR4.1, and transaldolase), oligodendrocyte-specific protein (287; 65), and microRNAs (miRNAs). Astrocytes – (alphaB-crystallin, arrestin, KIR4.1, and S100-beta). AlphaB-crystallin is expressed in multiple sclerosis plaques but is an atypical immune target; it binds immunoglobulin and not vice versa, and it is immunosuppressive. Antibodies to KIR4.1 appear in 50% of adult and pediatric multiple sclerosis sera and 40% of multiple sclerosis CSF but are seen in only 1% of other neurologic diseases and in no controls (305).
	• MicroRNAs in plasma may differ between forms of multiple sclerosis.
	• Alternative splicing of RNA, excessive in untreated disease, is likely to generate new protein targets (266).

Antibody responses to CNS antigens differ between patients, perhaps different types of inflammation, and varying CNS damage. Anti-myelin basic protein responses are normal or slightly increased in multiple sclerosis, unlike the strong responses seen in animal models. Antibodies to myelin basic protein are low in early multiple sclerosis and increase over time (272), but detection is inconsistent between laboratories. Some proinflammatory high-avidity human T-cell clones can recognize myelin basic protein (30). Anti-proteolipid antibodies in CSF are more common in women than men, in patients with later onset of multiple sclerosis or no family history of multiple sclerosis, and with low levels of CSF immunoglobulin and few oligoclonal bands (338). Antibodies to myelin oligodendrocyte protein are debatably elevated in all forms of multiple sclerosis. However, they exist in other inflammatory brain diseases, and in normal subjects, who also have anti-MBP T cells and activated anti-MOG memory T cells that produce IFN-gamma and nerve growth factor. Newly formed myelin does not express MOG and is resistant to inflammation. Faster progression correlates with anti-glycan IgM Abs, possibly provoked by CNS breakdown products that escape through the blood-brain barrier, B1 B cells, and the presence of some bacteria and fungi. Even if antibodies to brain antigens do not cause multiple sclerosis, they could modify disease course.

In contrast, post-vaccinal and post-infectious encephalomyelitis have defined target antigens. For instance, 1 in 220 people vaccinated with the Semple rabies vaccine--which contains central nervous system tissue--develop autoimmune encephalitis (similar to experimental allergic encephalomyelitis). Patients susceptible to this encephalitis, however, have a human leukocyte antigen (HLA) makeup that is distinct from that of multiple sclerosis (243).

The lack of a causative “multiple sclerosis antigen” suggests there is abnormal control of immune responses. Activated lymphocytes and monocytes might enter the central nervous system because of nonspecific adhesion to endothelial cells, become activated within the central nervous system, stay longer during trafficking through the central nervous system, and resist the normal CNS suppression of the immune response.

Non-antigen-specific immunity in multiple sclerosis inflammation.

Viruses. Viruses directly damage oligodendroglia or could share peptides with myelin proteins, triggering attacks by T and B cells through molecular mimicry. Viruses can enhance replication of other viruses, making linkage to a single virus difficult to determine.

Human endogenous retroviruses (HERV) make up 10% of the human genome but do not generate complete virions. Activated immune cells produce incomplete virus nucleic acids or proteins. Expression of HERV nucleic acids and proteins correlates with a more progressive disease course, and serum levels rise with long-duration multiple sclerosis. Activated astrocytes produce retrovirus-encoded syncytin, which is toxic to oligodendrocytes. The HERV envelop protein inhibits differentiation of oligodendroglial precursor cells. IFN-beta therapy strongly reduces the load of HERV products in blood. There is a surprising trend for less multiple sclerosis in HIV-infected patients, perhaps due to immunosuppression from HIV or anti-retroviral therapy.

Multiple sclerosis susceptibility is linked to a history of infectious mononucleosis, but not to acute Epstein-Barr virus (EBV) infections. Onset of infection in young adults increases the risk of developing multiple sclerosis 32-fold (37). Circulating Epstein-Barr virus-infected B cells are rare (1/10,000) but could be a reservoir of viral antigens. Infected B cells produce IL-6, which stimulates B cell proliferation, and B cells in multiple sclerosis produce higher than normal levels of IL-6. Antibodies to Epstein-Barr virus appear early in the course of multiple sclerosis and correlate with brain atrophy. This may partly reflect multiple sclerosis-characteristic high titers to many antigens and viruses; EBNA-1 and HHV6A seropositivity correlate. Smokers have higher anti-EBNA titers, along with high titers to many antigens and some therapeutics. EBNA1 protein cross-reacts with glialCAM in patients but also in healthy people. HLA-DR2 is over-represented in multiple sclerosis, and DR2-positive people have higher antibody titers to Epstein-Barr virus, measles, and rubella (57). Nonetheless, combination of HLA-DB1*15 positive and HLA-A*02 negative, with high antibody titers against Epstein-Barr virus nuclear antigen (EBNA), confers a 16-fold higher risk of developing multiple sclerosis than the opposite profile (127). Epstein-Barr virus-negative multiple sclerosis is very rare.

In children, seropositivity to EBNA-1 protein increases the risk of multiple sclerosis 3.8-fold; the disease is rare in seronegative children. Over 90% of children with multiple sclerosis are Epstein-Barr virus positive compared to 50% of healthy children. Shedding of virus appears in 50% of Epstein-Barr virus positive children with multiple sclerosis but in only 20% of Epstein-Barr virus positive healthy controls, suggesting impairment of immune control of EBV in multiple sclerosis (349). The EBNA-2 1.2 allele quintuples the risk of developing multiple sclerosis.

Anti-Epstein-Barr virus antibodies could arise from persistent infection of B cells, causing immune activation with more B cell costimulatory molecule expression and IL-6 secretion. Epstein-Barr virus-infected B cells become resistant to apoptosis and immune control. Viral latent proteins appear in meningeal germinal center-like areas in multiple sclerosis. Epstein-Barr virus RNA in white matter lesions of multiple sclerosis is associated with interferon-alpha production by macrophages and microglia (323). Virus DNA in CNS-draining cervical lymph nodes and saliva, and clonal anti–Epstein-Barr virus cytolytic T cells, indicate ongoing infection (284). Epstein-Barr virus nuclear antigen (EBNA-3) blocks the vitamin D receptor. Low vitamin D levels, perhaps reducing type I interferon, correlate with more Epstein-Barr virus shedding in saliva, linking two environmental factors important in multiple sclerosis.

Antibodies to cytomegalovirus, in contrast, correlate with better outcome and less risk of developing multiple sclerosis (37). Past cytomegalovirus infection confers a 0.27-fold lower risk of multiple sclerosis in children (339). Cytomegalovirus exhausts the immune system throughout the human lifetime, possibly inhibiting inflammation in multiple sclerosis.

Reports of varicella-zoster virus particles in multiple sclerosis brains have not been confirmed. Varicella-zoster virus DNA increases briefly in mononuclear cells during relapses, but varicella-zoster virus is generally assumed not to increase the risk of multiple sclerosis. However, Han Chinese patients who developed zoster in Taiwan were 4-fold more likely to develop multiple sclerosis in the next year than zoster-free patients (149).

Bacteria and chlamydia. Bacteria and chlamydia in posterior nasal sinuses and submucosa could trigger cytokine release and attack through cross-reactive antigens, superantigen activation of pathogenic T cells, responses to induced heat shock proteins (all trigger), and release of bacterial toxins (111). Conversely, parasite infestation is protective (59).

Diet. Diet affects immunity through direct effects on the microbiome and by changing immunity, eg, oral tolerance. Diet modifies macrophage and T cell function, membrane composition of immune cells, and prostaglandin synthesis. Fasting reduces monocyte number and inflammatory activity and improves chronic inflammation in animal models. Acinobacter and Akkermansia gut bacteria increase in untreated multiple sclerosis and, when transplanted, worsen experiment allergic encephalomyelitis in germ-free mice. These bacteria are countered by high-fiber diets and interferon-beta therapy, which increases immune-suppressive short-chain fatty acid transporters.

Genetics. Genetics control immune response to brain antigens and viruses and ability to repair CNS damage.

Oligodendroglia. Oligodendroglia exhibit defective function and repair of demyelination.

Sex. Multiple sclerosis is three times more common in women than men, and estrogens reduce attack rates in women.

Vaccinations. Multiple types of vaccinations tend to reduce the exacerbation rate. Of note, herpes zoster vaccinations reduce the rate of dementia in the general population by 20%.

Other mechanisms. Other mechanisms have been proposed, including toxins, microchimerism of circulating blood cells, and interrelations among endocrine, catecholamine, stress, and immune systems.

In the 1950s, it was theorized that CNS microvessels had poor blood flow in multiple sclerosis. Anticoagulants, however, failed to impact its course.

Venous stenting to reverse putative cerebral venous outflow problems (CCSVI) has demonstrated no benefit in controlled studies. Tens of millions of dollars in research money and medical costs, huge amounts of investigators’ intellectual energy, and misplaced hope by patients were directed at this therapy. Early studies that generated the hypothesis were carefully performed but have been difficult to replicate. Venous outflow is dynamic, and abnormalities can be reversed simply by drinking liquids. Many patients restrict fluid intake because of bladder urgency; others take diuretics for leg edema. Wearing neckties that obstruct venous outflow does not seem to be a risk. In atrophic multiple sclerosis brains, metabolic needs diminish and may simply reduce blood flow.

Pathogenesis

Multiple sclerosis is a demyelinating disease with brain and meningeal inflammation that also affects neuronal metabolism and survival. Demyelination and chronic cytokine exposure leads to brain atrophy, fatigue, cognitive loss, and neurologic abnormalities. The course of multiple sclerosis can be broken down into three phases:

(1) The initiating event for an exacerbation (inflammation, triggered by viruses and environment, with brain and hypothalamic lesions and sympathetic nerve damage)
(2) Recovery from relapses.
(3) Chronic progression.

Immunity underlying the CNS pathology in multiple sclerosis. The initiating event for the first exacerbation is unknown. Genetics and environment both play a role (231). Over 200 genes have weak links to multiple sclerosis; most are immune-related. Downstream, RNA expression in peripheral blood mononuclear cells is highly dysregulated, with 8800 abnormally expressed genes in untreated patients compared to healthy controls (91). Much of the signal is from immune genes. Multiple sclerosis drugs reduce the dysregulation.

mRNA expression in mononuclear white blood cells in multiple sclerosis

mRNA expression in mononuclear white blood cells in multiple sclerosis shows massive gene dysregulation and correction by long-term IFN-beta therapy. A. Partial responders (PR) to IFN-beta therapy, while clinically stable, 4 da...

Immune activation in multiple sclerosis is a multistep process, evolving over years. To create normal immune tolerance, medullary epithelial cells in the thymus express thousands of antigens that are also found in peripheral organs. During development of the immune system or later, an autoimmune cascade may start with thymic presentation of alternately spliced golli-myelin basic protein or other self or viral proteins in the context of excessive expression of costimulatory molecules (195). Cytokines, antigen affinity, and costimulation all have additive effects on immune responses. Type I interferons, dysregulated in multiple sclerosis, amplify antigen presentation. Nonetheless, no “multiple sclerosis antigen” has been identified.

Following peripheral activation by unknown stimuli, circulating T cells adhere to post-capillary venules in the choroid plexus, brain, and spinal cord. The T cells pass directly through the endothelial cells or breach the tight junctions of the endothelium. They then migrate into perivascular brain parenchyma and form plaques. Equivalent numbers of monocytes and T cells are present in plaques at early stages, but monocytes predominate in later multiple sclerosis lesions. Brain antigens and immune cells can emigrate to deep cervical lymph nodes and educate peripheral T cells. These T cells may then home back to the brain. In CNS plaques, the cellular infiltrate is associated with destruction of the inner myelin lamellae and dysfunction of oligodendroglia, neuronal loss, and astrocytic scarring.

Inflammation, reflected by Gd-enhancing MRI lesions, largely resolves in 2 to 8 weeks. Unseen by MRI, some immune cells remain in plaques. They are poised for reactivation and exhibit continued smoldering low-grade inflammation chronic active plaques and slowly expanding lesions, causing chronic axonal loss and demyelination.

Immune activation and dysregulation. Immune activation in peripheral blood precedes neurologic problems and MRI activity. Several weeks before attacks of multiple sclerosis and optic neuritis, concanavalin A mitogen-stimulated IFN-gamma and TNF-alpha production increases (26), as do IFN-gamma levels in serum (77), IFN-gamma-induced [Ca++] influx in T cells, and secretion of prostaglandins by monocytes. IFN-gamma, osteopontin, and IL-2 activate T cells and endothelial cells and induce costimulatory molecules that further enhance T cell proliferation and activation (247). CSF osteopontin correlates with progression.

During active multiple sclerosis, there are excessive levels of the activating zeta chain of the T cell receptor on CD4 cells (158), activation proteins (HLA-DR and CD71), costimulatory molecules on B cells (CD80/B7-1) (113), and chemokine receptors (CCR5 and CXCR3) on Th1 cells (18). Inflammatory cytokines and messenger ribonucleic acid for IL-2, IL-15, IL-17, IL-23, and IFN-gamma are elevated in mononuclear cells (320; 184; 274; 47). IL-1, IL-6, IL-15, and TNF-alpha are present in the CSF (194; 161). Inflammatory cytokines and monokines amplify immune responses. IFN-gamma "therapy" and granulocyte colony-stimulating factor (G-CSF) infusions trigger attacks of multiple sclerosis. IFN-gamma, a pro-inflammatory cytokine, is toxic to actively remyelinating oligodendroglia, and it activates monocytes and microglia. However, elevated IFN-gamma receptors on activated proinflammatory Th17 cells allow IFN-gamma to inhibit these cells through apoptosis (02), perhaps inhibiting the integrated stress response to protect mature oligodendroglia. Thus, cytokines affect timing, location, and degree of inflammation.

Control of inflammation is lost during attacks of multiple sclerosis. Concanavalin A-induced regulatory/suppressor T cell function drops (11). Low production of IL-10 removes another brake on Th1 cells. IL-15 levels rise in blood and in CSF monocytes during attacks and progression. These changes could lead to delayed-type hypersensitivity (Th1-type) immune reactions, and enhanced CD8 T cell cytotoxicity in the brain.

However, the Th1/Th2 dichotomy is too simplistic:

(1) Th1 and Th2 serum cytokines are surprisingly lower than in healthy controls according to a large-scale analysis (179). These cytokines do increase before attacks, known as a “cytokine storm” (180) but only to near-normal levels. IFN-beta therapy induces Th1 and Th2 cytokines in the CNS (51) and in peripheral immune cells (47; 337). Cytokine levels are dysregulated in multiple sclerosis, with poor correlations within and between Th1 and Th2 categories, but all are balanced in healthy controls (224). Balance returns towards normal with IFN-beta therapy. Linked to this benefit, microarrays of immune cell RNA from untreated patients show that the IFN-alpha/beta pathway is more dysregulated than the Th1 and Th2 pathway (348; 91).

(2) Therapy with anti-CD52 (alemtuzumab) depletes Th1 cells but also induces CD4 Treg (38), yet it does not stop progression in later multiple sclerosis.

(3) Excessive Th2 cytokines can also cause damage. A Th2-driven form of myelin-oligodendrocyte-glycoprotein (MOG)-induced experimental allergic encephalomyelitis causes lethal demyelination.

(4) Monokines and other cytokines are increased in CSF (194; 192). Genetics influence monokine levels. People with high IL-1/IL-1Ra (IL-1 receptor antagonist) ratios and high TNF-alpha/IL-10 ratios have a 6-fold higher risk of having a family member with multiple sclerosis (70).

(5) Th17 cells amplify autoimmune CNS inflammation and are suggested to be important in multiple sclerosis, although serum IL-17 levels are elevated in secondary progressive multiple sclerosis and correlate with MRI lesion load and brain atrophy. IL-6 plus transforming growth factor-beta generate IL-17-producing cells from naive CD4 cells. IL-23 maintains this population and induces IL-17 in memory CD4 cells. The inflamed blood-brain barrier and dendritic cells also help polarize naive T cells into Th17 cells (138). IL-4, IL-27, IFN-gamma, and IFN-beta all inhibit IL-17 production.

IL-17-expressing cells increase during exacerbations and are higher in multiple sclerosis plaques and CSF than in serum (82). The IL-17 receptor is also elevated on brain endothelial cells. CD4 and CD8 cells and oligodendrocytes in perivascular areas of active multiple sclerosis lesions produce IL-17 (322). Th17 cells simultaneously secreting toxic IFN-gamma, IL-17, TNF, and GM-CSF are increased in multiple sclerosis and correlate with MRI T1 lesions and are the sole survivors after glucocorticoid exposure (144). CSF levels of IL-17 and IL-8 correlate with the length of spinal cord lesions. Nonetheless, Th17 is difficult to detect in multiple sclerosis; it is at high levels and likely more pathogenic in demyelinating Devic disease/neuromyelitis optica (140).

(6) The aryl hydrocarbon receptor (AHR) binds dioxin, breakdown products of aromatic amino acids (eg, tryptophan), prostaglandins, compounds in cigarette smoke, products of ultraviolet light in the skin and flavonoids in vegetables, fruits, and tea (254). The AHR interacts with STAT transcription factors, retinoic and estrogen receptors, NF-kB, and the failed multiple sclerosis therapy, laquinimod. It induces inflammatory Th17 but also regulatory dendritic, NK (IL-10-secreting), Tr1 (IL-10 secreting), and T (Treg) cells. Culture conditions may explain published differences of AHR effects on Th17 function. Commonly used RPMI culture media has low levels of AHR ligands, but Iscove’s media has high levels of aromatic amino acids and is much more conducive to Th17 cell induction (329). Further modifying the aryl hydrocarbon receptor responses, sodium concentrations of these media are RPMI: 8.8 g Na+ = 383 mM/L = 191 mEq/L, Iscove (IMDM) media: 7.6 g Na+ = 330 mM/L = 165 mEq/L, and X-VIVO 15 media: 7.5 g Na+ = 326 mM/L = 163 mEq/L. The high levels of sodium in RPMI and an additional 30 to 40 mEq/L of Na added to Iscove media will induce Th17 (346).

Smoking products bind the AHR and inhibit NF-kB activation, reduce IFN-alpha and IFN-beta production, and increase virus infections (211). Because serum type I IFN levels and responses to IFN-beta are below normal in multiple sclerosis (93; 94), smoking is likely to amplify the IFN-beta deficit. Smoking triggers multiple sclerosis attacks and doubles the rate of brain atrophy (see Environment below); an effect through the AHR is possible. Effects on multiple sclerosis are likely to be complex. Nicotine inhibits immunity and experimental allergic encephalomyelitis (228). AHR ligands in germinal-center-like follicles in multiple sclerosis brain have not been studied, nor have effects of beauty salon vapors or diesel fumes, which suppress NF-kB and interferon-beta production. Vaping activates pulmonary endothelial cells.

Smoking increases the risk of onset and disease activity in lupus and amplifies disease activity in rheumatoid arthritis 1.5-fold. With certain HLA proteins and protein tyrosine phosphatase nonreceptor variant 22 (PTPN22), the risk of joint inflammation increases 20-fold. Smoking and inflammation induce homocitrulline, triggering antibodies to it that amplify severe rheumatoid arthritis. Possibly linked to smoking, aryl hydrocarbons reactivate Epstein-Barr virus as well as increase the risk of Sjogren syndrome and perhaps Sjogren-related Devic disease/neuromyelitis optica.

(7) CD2 is a costimulatory T cell molecule that binds CD58 (LFA-1). The conformation of CD2 may be altered in multiple sclerosis—there is a marked fall in avid RBC rosette-forming cells (CD2 on T cells binds CD58 on RBC), and some anti-CD2 antibodies do not bind CD2 (265). Simulation through CD2 is reduced in progressive multiple sclerosis. In addition, a DNA allele that increases CD58 mRNA is protective against multiple sclerosis (odds ratio = 0.82), and CD58 mRNA is elevated 1.2 times above normal in exacerbations and 1.7 times in remissions (69). There may be a reciprocal relationship between disease-activity-specific low CD2 function and CD58 expression. Activation through CD2 increases regulatory CD4 T cell number and function; effects of CD2 on cytolytic and regulatory CD8 cells are unknown.

(8) CD8 clones expand in blood, CSF, and multiple sclerosis plaques; CD4 clones do not. Cytolytic CD8 cells and monocytes in plaques directly damage neurons and axons. Many of these CD8 cells are activated, react with EBV-infected B cells, and secrete toxic IL-17, suggesting they are mucosa-associated invariant (MAIT) T cells (322; 328). Melanoma cell adhesion molecule-positive CD8 cells are elevated in multiple sclerosis CNS, produce IL-17, IFN-gamma, and GM-CSF, and kill oligodendroglia.

(9) CD8+,CD28- regulatory/suppressor cell function is an important component of immune suppression in multiple sclerosis. Without inhibitory feedback, inflammation can become self-sustaining. During exacerbations, the number of regulatory CD8 cells drops and surface CD8 protein diminishes, noted in the first study to quantitate membrane CD8 expression on lymphocytes (263). Importantly, concanavalin A mitogen-induced suppressor function drops during attacks of multiple sclerosis (11; 154; 62). The T cells that suppress immune reactions are predominantly CD8+CD28- (10; 66). CD8 cells have more potent suppressor effects than CD4 cells in multiple sclerosis. CD8 suppressor cells form a 3-way bridge with monocytes to destroy pathogenic CD4 cells that express HLA-E (312; 62). CD8+,CD28-,FoxP3+ suppressor cells also induce tolerogenic ILT3 and ILT4 molecules on endothelial cells (196; 145) and on antigen-presenting cells. During exacerbations, high levels of IL-15 and IFN-gamma induce expression of the inhibitory NG2A protein on CD8 cells, further diminishing their suppressor function (62). In mice, similar CD8,CD122 regulatory cells produce IL-10 to inhibit proliferation and IFN-gamma production by CD8 cytotoxic cells. Four classes of multiple sclerosis therapy induce CD8 suppressor cells (below).

Transfer of specific neuroantigen-reactive CD8 cells inhibits experimental allergic encephalomyelitis (350). In CD8 knockout mice, attacks resolve, but later relapses still occur. This suggests that regulatory CD8 cells do not terminate inflammation but do prevent recurrent attacks in mice. Generalizations across species are suspect, however. The major suppressor cell subpopulation in mice is CD4+CD25+ T regulatory cells; in multiple sclerosis, the more potent subset is CD8+CCD28-.

The defect in mitogen-induced CD8 suppressor cell function in multiple sclerosis correlates highly with clinical activity (r = 0.79) (10), far better than enhancing MRI lesions correlate with clinical disease (r = 0.25) or serum cytokine levels (163). The CD8 suppressor defect in multiple sclerosis is corrected with IFN-beta, glatiramer acetate, fingolimod, ocrelizumab, beta2-adrenergic agonists, and Fc receptor ligands. Monitoring of suppressor cell function, or expression of CD8, ILT3, or CD80, or specific Th1, Th2, and Th17 markers could predict impending attacks of multiple sclerosis, could differentiate multiple sclerosis attacks from transient fever-induced worsening, and could reflect therapeutic responses to drugs.

(10) CD4+ CD25++ (CD39+) FoxP3+ T regulatory cells (Treg), CD56bright NK suppressor cells, and follicular regulatory T cells have reduced function in multiple sclerosis (310). CD4 Treg can function with or without contacting target cells. They shed immune-inhibitory TNFRII molecules and can create a tissue microenvironment that induces other immune suppressive populations, “infectious tolerance.”

Tr1 CD4 suppressor cells secrete inhibitory IL-10 in multiple sclerosis, but levels are 6-fold less than normal. Multiple sclerosis CD4 cells are also resistant to inhibition by IL-10 (201). Memory CD4 Treg, unlike CD8 Treg, return to normal levels in progressive disease (330). The environment in the eye is immunosuppressive; very small amounts of retinal antigens create CD4 CD25+ cells that inhibit immunity in mice. The immunologically privileged CNS is likely to behave similarly. CD4 Treg development requires IL-2, IL-7, vitamin A, TGF-beta, and indoleamine dioxygenase (induced by IFN-beta). CD4 Treg can also be induced by cAMP agonists and apoptotic cells, including antigens from dying brain cells draining to deep cervical lymph nodes.

(11) Thymic export of new T cells is reduced in multiple sclerosis. The age of these cells can be quantitated; each time peripheral T cells divide, the number of T-cell receptor recombinant DNA excision circles (Trec) per cell is halved. Recent thymic emigrants (RTE), including new naive T cells and Tregs, are reduced in relapsing-remitting multiple sclerosis (124). Peripheral Treg precursors are highly sensitive to endogenous signals that control development of mature peripheral Treg (232). Using RTE as a measure, the immune system in multiple sclerosis ages prematurely and is 30 years older than that of healthy controls (133).

(12) B cells have direct effects on immune regulation and brain destruction (209). Activated CSF B-cell clones secrete antibodies to generate oligoclonal bands. B cells also present antigen to T cells, secrete cytokines, and sequester Epstein–Barr virus and JC viruses. B cells secrete pro-inflammatory IL-6, GM-CSF, TNF-alpha, and chemokines. IL-6 enhances generation of destructive Th17 cells. In contrast, B cells can produce anti-inflammatory IL-10 and IL-35 as well as nerve growth factor and brain-derived neurotrophic factor, which may help repair the CNS. Potentially pathogenic inflammation- (IFN-gamma) and virus- (TLR9) triggered B cells (327), and microbiota-reactive IgA+ B cells, some producing IL-10, traffic into the CNS during exacerbations (251). Despite these data, there are few B cells in the parenchyma, but many in germinal center-like areas in the meninges. Anti-B cell therapies will, therefore, have complex effects on B-cell regulation of immunity because of pro- and anti-inflammatory effects of B cells and suboptimal penetration of many therapies into the brain and meninges.

B cells are activated in multiple sclerosis. Compared to healthy controls, naïve B cells secrete half as much inhibitory IL-10 after stimulation with anti-CD40 (a model of bystander T cell activation) or with anti-B cell receptor plus anti-CD40 (B cell plus T cell activation) (80), although the same laboratory later stated that Bregs may have increased function in multiple sclerosis. Circulating B cells in multiple sclerosis express high levels of costimulatory molecules (CD80/B7-1), pushing them above a signaling threshold to enhance inflammation (114). B cells are potent antigen-presenting cells because they are exquisitely focused against specific antigens. B cells are activated by B cell activating factor (BAFF), which is made by myeloid cells. CSF BAFF and CXCL13, a B cell attracting chemokine, increase during relapses and in secondary progressive multiple sclerosis (256).

CSF BAFF correlates with IL-6 and IL-10 levels, suggesting that these factors amplify B cell function and CSF antibody production. CSF CXCL13 is elevated in all forms of multiple sclerosis and correlates with CSF white cell and B cell number, IgG synthesis, and MRI activity. The number of CSF B cells and plasmablasts correlates with active MRI lesions in the brain.

High CSF immunoglobulin synthesis and high CSF antibody titers to measles virus were reported in the 1950s. CSF IgG and oligoclonal bands are present in more than 95% of patients. Bands are a sensitive and specific diagnostic test that reflects CNS inflammation and cortical lesion load but do not correlate with prognosis. IgG kappa light chains in CSF are a more sensitive test, but slightly less specific, and do not require a paired serum sample. However, the serum/CSF kappa index reflects prognosis.

In clinically isolated syndromes, B cell clonal expansion is reflected by rearranged mRNA and certain heavy chains (VH4 or VH2) and is linked to development of multiple sclerosis, yet these antibodies do not predominantly react against myelin (27). In progressive multiple sclerosis, CSF and brain B cells clonally expand and are present in germinal center-like areas in the meninges. CSF and serum antibodies recognize viruses, myelin proteins, axons (triose-phosphate isomerase), DNA (ANA), and unknown antigens. Over 50% of brain plaques contain antibodies plus complement, yet the antibodies do not cause demyelination (186). Some anti-brain antibodies enhance remyelination in mice, but not in humans.

(13) Chemokines attract immune cells. Monocytes in multiple sclerosis secrete excessive CXCL8 (IL-8) to attract other monocytes. IL-8 also attracts polymorphonuclear neutrophils, but these cells are rarely seen in multiple sclerosis CSF or brain. In Japanese optico-spinal multiple sclerosis, however, there is high IL-8 and IL-17 and Th1 (IFN-gamma) and Th2 (IL-4 and IL-5) cytokines. In a subset of patients with this Japanese NMO/Devic-like variant, IL-8 in CSF and neutrophils in lesions correlate with spinal cord lesion formation (140). IFN-beta therapy decreases IL-8.

(14) Monocytes, and to a lesser extent, microglia present antigens and amplify immune responses. They communicate with cells hundreds of microns away through tunneling nanotubes that transmit calcium ions and antigens and continuously modify neuronal networks. They over-express receptors for immunoglobulins and are activated by low levels of serum receptor for advanced glycation end-products (RAGE). Inhibitory molecules on monocytes (HLA-G, ILT3/LILRB4) are reduced in multiple sclerosis but are upregulated by IFN-beta (213; 145) and by vitamin D, IL-10, and CD8 suppressor cells.

Microglia in the brain release nitric oxide, oxygen radicals, complement, proteases, and cytokines. CSF nitric oxide metabolites correlate with gadolinium-enhanced MRI lesions, clinical activity, and progression of multiple sclerosis. Nitric oxide also modifies brain proteins to form nitrotyrosine, creating neo-antigens in the brain and generates antibodies to S-nitrosocysteine in the CNS (40). Myeloid dendritic cells in secondary progressive multiple sclerosis are activated and pro-inflammatory (156). Peripheral monocytes secrete excessive nitric oxide, which is neurotoxic and damages oligodendroglia, but also eliminates activated pathogenic T cells (See “Recovery from relapses,” below.).

(15) Plasmacytoid dendritic cells are weak as antigen-presenting cells but are the major source of type I interferons. They are more frequent in early multiple sclerosis and during relapses in some studies. However, in multiple sclerosis these cells produce less IL-10, less IFN-alpha (306), and induce Th17 cells.

(16) Myeloid suppressor cells are precursors of macrophages, dendritic cells, and granulocytes. They increase in number during exacerbations (140/million mononuclear cells) versus normal controls (5/million), fall during stable disease (15/million), and have potent function in multiple sclerosis (139). They promote function of regulatory B cells and CD4 T cells and suppress activated CD4 cells on contact.

Many immune subsets and cytokines are abnormal in untreated multiple sclerosis. Underlying this, RNA microarrays show 8000 dysregulated genes (91) and abnormal alternative splicing of RNA in a largely different subset of 3600 genes (266). Serum cytokine levels are subnormal and are not correlated, unlike healthy controls where Th1 and Th2 cytokines are balanced (179). Abnormal gene expression, RNA splicing, serum cytokines, and low serum type I interferon levels are largely corrected by IFN-beta therapy.

Trauma, inflammation, and immunity. Trauma and stress were proposed by some to cause multiple sclerosis and trigger exacerbations (207; 246; 46; 178). However, linkage to exacerbations is nonexistent when stress, trauma, and concomitant clinical manifestations of multiple sclerosis are carefully analyzed (293; 294; 300). Stress in the home and physical abuse during childhood appear to prevent multiple sclerosis. Gunshot wounds and SCUD missile attacks actually seem to protect against exacerbations (293; 226), although another war report suggests increased exacerbations (118). However, local irradiation of the brain increases lesions of multiple sclerosis within the radiation field, possibly by disrupting or activating the blood-brain barrier (222) and activating microglia. Following a stroke or brain injury, activated monocytes and macrophages persist in multiple organs (297).

Autonomic control and damage in multiple sclerosis. The hypothalamus regulates autonomic functions, body temperature, sleep, and sexual activity. Hypothalamic corticotrophin releasing hormone (CRH) begins an endocrine cascade to adrenocorticotropic hormone and then to cortisol production. Serum cortisol feedback and exogenous steroids turn down corticotrophin secretion.

Hypothalamic plaques are common in multiple sclerosis and disrupt endocrine regulation (135). Neurons that secrete regulatory hormones are localized to periventricular and arcuate nuclei and are, thus, perhaps more susceptible to CSF toxins. Surviving myelin bundles are next to HLA class II positive microglia. Inflammation in the hypothalamus may explain the high number of double-positive corticotrophin and arginine-vasopressin neurons that are unique to multiple sclerosis, especially in disease of long duration. Arginine-vasopressin potentiates the action of corticotrophin on adrenocorticotropic hormone (ACTH) release. The resultant elevation in cortisol could inhibit inflammation because high numbers of corticotrophin-releasing factor/arginine-vasopressin neurons correlate with low hypothalamic lesion load. Similarly, rats with high corticosterone are protected against experimental allergic encephalomyelitis.

The hypothalamic-pituitary-adrenal (HPA) axis is hyper-responsive to corticotrophin-releasing hormone, especially in primary progressive multiple sclerosis (313). Chronic HPA axis overactivity renders cells insensitive to glucocorticoids, allowing them to escape from immune restraint. Levels of cortisol, adrenocorticotropic hormone, and dehydroepiandrosterone, and the number of cells secreting corticotropin releasing hormone are increased most in progressive and active forms of multiple sclerosis (352).

Steroid-regulated diurnal migration of B cells from bone marrow to blood is likely to be disrupted. Acute and chronic inflammation induces high serum cortisol levels, causing systemic and local steroid resistance. IL-1alpha, produced by activated macrophages (M1), inhibits glucocorticoid receptor translocation to the cell nucleus (238). High levels of tumor necrosis factor, IL-1, and IL-6 correlate with hypothalamic-pituitary-adrenal axis (HPA) activation and fatigue. During active multiple sclerosis, the hypothalamic-pituitary-adrenal axis and immune cells are hyporesponsive to dexamethasone feedback (267). Conversely, cyclic adenosine monophosphate (cAMP) agonists (prostaglandins, beta-adrenergic agonists such as terbutaline, and some antidepressants) enhance steroid receptor translocation and could potentiate glucocorticoids and normalize the HPA axis. Weak steroid response correlates with high CSF white blood cell counts and with enhancing lesions on MRI (89). Mechanisms for resistance to steroids include (1) downregulation from chronic high cortisol (mildly increased in multiple sclerosis), possibly from adrenocorticotropic hormone released by immune cells (261; 268; 189); (2) alterations in steroid receptors; and (3) interaction with other signaling pathways.

During pregnancy, the exacerbation rate falls (32). Regulatory cytokines and hormones such as estriol act together to frustrate Th1 responses and cause immunosuppression. Estriol therapy reduces exacerbations in multiple sclerosis. CD4 and CD8 regulatory T cells tolerize against the fetus. They persist after delivery, perhaps correcting the regulatory defect in multiple sclerosis. ILC2 cells in the developing meninges produce IL-4 and IL-13 to enhance inhibitory synapse formation, which later promotes social behavior. In contrast, perhaps, mild maternal infections during mouse pregnancy enriches IL-17+ cells in the small intestine of the pups.

Recovery from relapses. As clinical symptoms wane, suppression of inflammation is linked to a rise in inhibitory Th2 cytokines, immunoglobulins, and glucocorticoids (269) and rebound of subnormal suppressor T cell function (10). In addition, axonal sodium channels redistribute in ravaged but surviving axons, and the brain remyelinates and rewires (compensatory adaptation; functional reorganization of neurons and synapses).

Inflammation is turned off by apoptosis and suppression of activated immune cells. Apoptosis of Th1 cells is mediated by steroids (endogenous or therapeutic), IFN-gamma (108; 02), TNF-alpha, and nitric oxide. IFN-beta causes apoptosis of Th17 cells, which express high levels of the type I interferon receptor (82). Unfortunately, some of these regulatory compounds are also toxic to neurons and oligodendroglia (TNF-alpha, high levels of IFN-alpha, glutamate, and nitric oxide). Glucocorticoid treatment has no long-term benefit and actually spares a subpopulation of toxic IFN-gamma, TNF-alpha, and GM-CSF producing Th17 cells (144).

A subgroup of macrophages (anti-inflammatory M2 family) secrete neuroprotective compounds during recovery. These macrophages are P2RY12 positive (homeostatic microglia) and produce platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor beta (TGF-beta), insulin-like growth factor 1 (IGF-1), neural growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT3). BDNF is expressed in lesions by T cells, microglia, and astrocytes. Immune cells secrete more BDNF during relapse, but levels fall with progression. Other neurotrophic factors rise after relapses, including glial derived neurotrophic factor (GDNF), NT3, NT4, NGF, and possibly ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF). Foamy macrophages, after ingesting myelin, secrete anti-inflammatory IL-4, IL-10, and prostaglandin (PGE). Staph protein A-activated monocytes produce ten times more IL-10 (3000 pg/ml) than lymphocytes (125). In turn, IL-4, IL-10, and granulocyte-macrophage colony-stimulating factor (GM-CSF) induce microglia and monocytes that have anti-inflammatory properties. In focal and traumatic brain injury, and perhaps in multiple sclerosis, activated microglia phagocytose CNS debris. Triggering receptor expressed on myeloid/microglial cells (TREM2) binds phospholipids and pathological amyloid. It associates with transmembrane adaptor (DAP12) on microglia and activates SYK to help clear A-beta amyloid plaques. However, this microglial activation may be detrimental in multiple sclerosis lesions.

IFN-beta and IFN-gamma cause macrophages to produce indoleamine 2,3 dioxygenase, an anti-inflammatory compound that induces regulatory T cells. Glatiramer acetate activates type II monocytes (M2 family), which induce Th2 cells and regulatory CD4 T cells, and these inhibit experimental allergic encephalomyelitis (341).

Remyelination occurs in most lesions soon after lesion onset and lasts for up to 6 months. It prevents axonal loss and slows progression. Remyelination is the normal default response to insults, reinforcing the need to reduce ongoing inflammation. Remyelination is quite extensive in 20% of patients and seen in more than 40% of MRI lesions. It occurs in both relapsing-remitting and primary progressive disease and in both early and late multiple sclerosis (240). It can be prominent in older patients, in disease of long duration, and in subcortical and deep white matter, but it is infrequent in periventricular plaques. Generation of new oligodendrocytes aids brain plasticity and learning, and oligodendrogenesis is promoted by neuronal activity.

Evolution of the progressive clinical course: many possible causes. Repeated exacerbations and remissions change to a progressive clinical course approximately 10 years after disease onset. Clinical remissions, associated with T- and B-cell-mediated immunity, wane. However, constant low-grade immune activation smolders and monocyte-mediated damage begins to predominate. In progressive multiple sclerosis, cumulative loss of oligodendroglia and neurons increases demands on surviving, but compromised, cells.

One theory for the evolution from relapsing-remitting to progressive multiple sclerosis is that early subclinical neurodegeneration simply becomes noticeable at some point. However, patients who continue to have frequent relapses after the first 2 years are less likely to become progressive (286), and superimposed relapses actually slow worsening in progressive-from-onset patients (134). This suggests that there is a transformation from relapsing-remitting to progressive multiple sclerosis. Current drugs reduce relapses and relapse-associated worsening, but only partially slow progression. The mechanism for this failure of immune regulation and CNS repair is unknown (195; 75), but there are many hypotheses for the mechanism:

Changes that may provoke the transition from relapses to progression, interplay of immunity, genetics, and pathology that varies among patients.

(1) Interferon signaling is near-normal in stable relapsing-remitting disease but is subnormal during exacerbations and becomes continuously subnormal in mononuclear cells from patients with progressive disease (93).

(2) Weak CD8 suppressor T cell function, seen intermittently during exacerbations, becomes continuous with progression (264; 11). Over time, there is loss of peripheral immune tolerance and loss of many immune regulatory pathways (91).

(3) Naive CD4 T cells that express high levels of immune response genes (activation markers, pro-apoptotic markers, CD28, chemokines, vitamin D receptor, and TLRs 1,2,4,7) correlate with rapid transition from relapsing to progressive multiple sclerosis (353).

(4) T cell clones from patients with progressive multiple sclerosis express costimulatory CD80 and CD86 molecules and can present antigens. These cells become insensitive to steroids, which only weakly inhibit their proliferation and cause little apoptosis, akin to a “pre-leukemic state” (61). They are also resistant to growth inhibition by TGF-beta.

(5) Spontaneous and activation-induced apoptosis of pathologic T cells is impaired during clinically active multiple sclerosis (356; 291), so autoimmune cells are not eliminated.

(6) Fluctuating dysregulated Th1 and Th2 immunity shifts to chronic neurogenerative innate inflammation. Gene dysregulation in mononuclear cells in untreated relapsing/remitting multiple sclerosis with 8800 differentially expressed genes versus healthy control mononuclear cells falls to 3600 in secondary progressive disease (91; 104), and these disturbed genes are now often in repair pathways. In parallel, CSF cells have an autoimmune profile in low-EDSS patients but a neurodegenerative profile in high-EDSS patients (129).

(7) Adhesion molecules are shed from the lymphocyte surface in relapsing-remitting and secondary progressive disease but not in primary progressive multiple sclerosis (81). This suggests that T cell-endothelial cell adhesion is most abnormal in relapsing disease.

(8) Germinal center-like areas appear in the leptomeninges, often deep in sulci, in secondary progressive multiple sclerosis. They are less frequent in relapsing and primary progressive multiple sclerosis. Organized sites with chronic B-cell activation suggest there is loss of immune control, and cytokine toxins spew out from these germinal center-like areas. Antibodies to many targets generally increase more with progression. A subarachnoid lymphatic-like membrane (SLYM) lines meningeal sinus endothelial cells, allowing exchange of small molecules between venous blood and CSF. Perhaps related, there is a high TSPO PET signal in bones at the temporal pole and base of skull, suggesting inflammation of the calvarium in multiple sclerosis. The dura is only marginally affected.

(9) Gadolinium-enhancing MRI lesions decrease in frequency during progression, possibly from a change in the makeup of inflammatory peripheral or CNS cells or in endothelial cell activation.

(10) Patients with primary progressive multiple sclerosis and high MRI T2-weighted lesion volume have excessive IFN-gamma production and rapid T cell migration through endothelial cells (248).

(11) Monocytes and microglia show excessive proinflammatory innate immunity. Monocytes produce 5- to 10-fold more IL-12 and IL-18, and more IL-23, in progressive multiple sclerosis (19). These interleukins induce IFN-gamma and allow dendritic cells to activate pro-inflammatory Th1 cells (156). Macrophages (pro-inflammatory M1 family) and Th1 and Th17 cells activate astrocytes to secreteTIMP-1 and CXCL10 (IP-10), which are toxic to oligodendrocytes. In contrast, protective IL-10, PGE, and BDNF decrease. Low IL-10 is associated with more disability and more MRI lesions. Immune cells in secondary progressive multiple sclerosis also secrete high levels of kallikreins and destructive serine proteases; both are associated with more disability.

(12) Plaques contain more monocytes and fewer T cells in chronic disease. Perhaps reflecting a shift to innate immunity, anti-T cell therapy has no or minimal clinical benefit in progressive multiple sclerosis.

(13) Neurotrophic abilities are lost as disability progresses, both in the central nervous system and in peripheral blood cells. Nerve growth factor produced by endothelial cells drops with increasing disability (31) as does BDNF produced by T cells (125). Chronic defeat stress, and possibly the stress of ongoing brain inflammation, reduces BDNF levels through di-methylation of the BDNF gene, a DNA-repressive modification (321). N-acetylglucosamine (GlcNAc) serum levels are low in progressive disease, perhaps reducing N-glycan branching, leading to demyelination and inflammation.

(14) Inexorable damage. In animal models, noninflammatory damage from cuprizone is followed by completed remyelination and is then clinically stable for some time. However, after 6 months, slow axonal degeneration crosses a threshold, and mice lose clinical function (197). WNT repair pathway expression in progressive disease declines in mononuclear cells, coinciding with reduced repair capability (104); WNT expression increases with exercise. Residua from old lesions plus ongoing inflammation combined with aging cause relentless loss of function and atrophy. In addition, leukocyte telomeres are shorter in secondary progressive disease, perhaps from environmental or endogenous stressors, and this shortness reflects premature aging and correlates with rate of progression (126).

(15) Brain atrophy is largely periventricular in relapsing multiple sclerosis. In progressive multiple sclerosis, atrophy predominates in the deep gray matter (102) and the cortex (230). Deep cortical invaginations are most affected and abut many germinal center-like inflammatory areas (171). At the transition to progressive multiple sclerosis, gray matter loss accelerates and is the main contributor to total brain atrophy (101), and cortical remyelination and plasticity fail. In a prospective study, cortical lesion load and, most significantly, cerebellar cortical and white matter volume predict the change to progression (50). In contrast, white matter damage is obvious in relapsing/remitting multiple sclerosis but does not predict progression. Retinal nerve fibers and macular ganglion cells thin faster in progressive than in relapsing multiple sclerosis, and damage is not slowed by therapy in progressive disease (302).

(16) Cord atrophy and neuronal loss are present in all forms of multiple sclerosis. Atrophy correlates with progression and disability, especially in those with higher EDSS scores. The cord gray matter is reduced in progressive compared to relapsing disease, is most pronounced in the cervical cord, begins 4 years before clinical progression (34), and is associated with 60% to 90% loss of cord synapses and 50% loss of anterior horn neurons (242). Anterior horn cells decline with normal aging but not this quickly. Cord lesions often damage sympathetic fibers (see 21).

(17) Axonal damage markers in CSF after a first attack predict conversion to definite multiple sclerosis (43). Tau and neurofilament proteins (40%) are slightly better than MRI (34%) as predictors. Both increase further during exacerbations and in secondary progressive multiple sclerosis, reflecting ongoing damage. Serum neurofilament light chains (NfL) peak 8 weeks after onset of gadolinium enhancement. Amplifying symptoms and causing cellular stress, axonal energy demand is increased in parallel with detached and uncompact myelin plus unmasked potassium channels at the nodes of Ranvier in normal-appearing white matter (324).

(18) Destruction of oligodendrocytes continues at a faster pace in secondary progressive multiple sclerosis than in relapsing-remitting multiple sclerosis, and there is more myelin basic protein-like material in urine.

(19) Oligodendrocyte precursor cells are lost as plaques accumulate. Oligodendrocyte precursor cells are also not recruited to the lesions, fail to differentiate, and do not remyelinate, possibly from inhibitory factors in plaques such as chondroitin sulfate, hyaluronan, or from inhibitory molecules on demyelinated axons such as polysialylated-neural cell adhesion molecule (PSA-NCAM, NOGO, and RGM) (105). In chronic plaques, progenitor oligodendrocytes extend processes to axons but do not wrap around axons. Axons that spurn the oligodendrocyte remain dystrophic, swollen, and vulnerable to insults (53).

(20) Activated astrocytes also inhibit extension of oligodendrocyte processes. Normal astrocytes express beta2-adrenergic receptors and secrete adenosine in response to norepinephrine. Their products dynamically change neuronal firing, suppress synaptic strength, reduce major histocompatibility complex class II and adhesion molecule expression, inhibit immune responses, and induce secretion of trophic factors and lactate, an energy source for axons and oligodendrocytes. In multiple sclerosis and in Alzheimer disease, adrenergic receptors are absent from astrocytes (72); this is associated with more neuropathology. Loss of these receptors may overcome immune privilege (above) and allow overactive immune responses in the central nervous system.

(21) Sympathetic nerves innervate the gut and bone marrow and inhibit immunity (336). A reflex arc of sensation monitors the gut with transmission to the CNS, and memory of gut immunity is stored topographically in the insular cortex. Motor efferent output affects the gut microbiome. Situated next to monocytes and macrophages, nociceptor neurons sense bacterial invasion and secrete CGRP to inhibit invasion and also feed back into the nervous system. Sympathetic effects on bone marrow and T cell homing are also of interest because bone marrow has more polymorphonuclear and myeloid cells, and fewer B and NK cells in untreated multiple sclerosis (292).

Many patients have constipation, perhaps linked to loss of enteric neurons, further disrupting this reflex arc (266).

Disrupted sympathetic pathways arise from a gradual increase in cord plaque burden. Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis (34), and autonomic responses are frequently disrupted in progressive forms of multiple sclerosis. A "strategic hit" to central autonomic pathways may interfere with the immuno-inhibitory tone from spinal sympathetic adrenergic fibers that innervate the spleen (155). The fibers contact choline acetyl-transferase-containing T lymphocytes that secret acetylcholine and also shift monocytes to an M2 anti-inflammatory phenotype. With autonomic loss in progressive multiple sclerosis, a form of denervation supersensitivity appears in immune cells, and beta2 adrenergic receptors are overexpressed on CD8 T cells. These cells have exaggerated cyclic AMP responses that can affect suppressor CD8 T-cell function and innate immunity. Oral terbutaline, a beta2-adrenergic agonist, increases CD8 suppressor function and, thus, could be therapeutic in progressive disease (Reder et al unpublished). Vagal nerve stimulation is under investigation for multiple sclerosis.

The role of sympathetic input, enteric neuron damage, gut-innervating pain neurons, and constipation and the effects of disease-modifying therapies and symptom treatments (opiates, antibiotics, gabapentin, steroids) versus the microbiome in multiple sclerosis need to be explored.

(22) Adrenals increase in size, cortisol levels rise, and feedback inhibition of the hypothalamic-pituitary-adrenal axis by glucocorticoids is abnormal in progressive multiple sclerosis, perhaps from excessive production of AVP/CRH in the plaque-filled hypothalamus. High glucocorticoid levels, endogenous and therapeutic, are linked to hippocampal atrophy. Glucocorticoid therapy no longer suppresses multiple sclerosis symptoms. Hypercortisolemia may be corrected with antidepressants.

(23) Therapies directed at T and B cells, which are effective in relapsing or transitional multiple sclerosis, lose some efficacy in purely progressive multiple sclerosis. These include alemtuzumab, glatiramer, IFN-beta, mitoxantrone, fingolimod, natalizumab, chemotherapy, IVIG, and rituximab. The therapy term “highly effective” is based on relapses and MRI benefit, not progression.

Clinical characteristics interact with the above factors. Progression and poor prognosis are accelerated in those with poor recovery after attacks, in older patients and men, and in those with sphincter, motor, and multiple system dysfunction, and with comorbid illnesses that blossom with aging. There is more brain atrophy, especially in the cortex during progression independent of relapse activity (PIRA), paralleling accumulation of disability. Finally, progressive patients are generally older, and aging itself is toxic. Remyelination and brain repair slows, microglia are activated, brain atrophy accelerates, glymphatic drainage is reduced, estrogen levels fall, telomere length declines, thymic T-cell output falls, and the immune system becomes senescent. Markers of senescence in neurons and glial cells rise 10- to 50-fold in plaques compared to healthy brain, especially in active lesions (237). These markers are linked to inflammation, cell cycle arrest, neurodegeneration, and loss of oligodendroglia maturation and correlate with earlier disability and death.

Pathology of the multiple sclerosis lesions. Multiple sclerosis plaques arise in both gray and white matter throughout the brain and spinal cord. They may be preceded by clusters of activated microglia, microglial nodules, in the white matter (324). Lesions have predilection for periventricular and periaqueductal sites, and optic nerves are almost always involved. Cord lesions are often subpial. Even “normal appearing white matter” is abnormal on magnetic resonance spectroscopy. On histology, there is significant axonal loss, especially near plaques.

A plaque is a well-demarcated area with myelin loss, inflammatory cells, gliosis, and often partial preservation of axons and neurons. Demyelination usually predominates, but in some cases, axonal loss is severe (316). Mitochondria are increased in axons and astrocytes of active and inactive lesions, indicating energy need, but can become dysfunctional during inflammation. Microglia of inactive lesions convert back to a homeostatic phenotype.

Swollen, hypertrophied astrocytes at plaque edges contain dense core particles and sometimes endocytosed oligodendroglia. Perivascular end-feet of astrocytes are damaged early in plaque formation, reminiscent of the pathology in neuromyelitis optica. Astrocytes are initially hypertrophic or “gemistocytic” with high levels of GFAP. When stimulated by IL-9, they produce CCL20, which attracts CD8 and Th17+ CD4 T cells. Astrocytes also produce potentially beneficial trophic factors, BDNF, TrK receptors, and VEGF (188). Months to years later, they become fibrillary and form fibrous scars (sclerosis; gliosis). GFAP levels reflect astrocyte activation.

The periventricular location of plaques is explained by multiple theories: damage from CSF toxins or cytokines, regional variation in microglia or capillary pericytes, and slow blood flow in post-capillary venules that facilitate T cell adhesion. Local toxins are unlikely because abluminal molecules diffuse throughout the brain within 6 minutes, facilitated by arterial pulses (273). Rapidly diffusing cytokines should activate pericytes or endothelial cells throughout the CNS, unless toxins are efficiently bound by nearby cells. MRI suggests that a slow flow rate through periventricular veins allows immune cells more time to attach to endothelium (174). Slow flow, less than 50% of other brain areas, occurs despite the reduced diameter of intra-lesional veins and increased diameter of extra-lesional veins (109). All plaques are perivenular on MRI (311), and areas with high vein density are most frequently affected. In radiologically isolated syndromes without clinical activity, only lesions surrounding a central vein predict development of multiple sclerosis (253).

Choroid plexus cells are activated and swollen, with HLA-DR and VCAM-1 expression in macrophages, dendritic cells, and epiplexus cells (331). The choroid is an important site for antigen presentation and for the earliest T, B, and NK cell entry into the CNS, leading to CSF-mediated surface-in or ependymal-in gradient of thalamic damage (88). The activated choroid plexus is enlarged in multiple sclerosis, but not in NMO. Enlargement is linked to periventricular neuroinflammation, brain lesions, and atrophy.

The blood-brain barrier consists of specialized endothelial cells connected by tight junctions in the lumen of blood vessels. On the abluminal surface are vascular smooth muscle cells and pericytes. Surrounding these cells, the inner layer of the basement membrane includes endothelial cells and pericytes. Astrocyte foot processes generate the outer layer. A few areas, such as the area postrema, lack tight junctions yet have no increase in plaques. This discordance suggests that tight junction breakdown paired with cellular disruption and activated endothelial cells in the postcapillary venules can actively attract immune cells into restricted CNS areas.

The capillary endothelium is abnormal in multiple sclerosis and in experimental allergic encephalomyelitis (217). In 1872, Rindfleisch described abnormal blood vessels in all multiple sclerosis lesions (188). Active plaques appear on MRI because of leakage though the barrier and perhaps from Gd uptake by activated endothelial cells. The transfer rate increases 3-fold in young patients and 1.6-fold in older patients, even though 10 of 13 patients in this study were on therapies (309). Lack of Gd+ lesions in progressive multiple sclerosis suggests there is less breakdown of the blood-brain barrier, yet serum proteins extrude through the blood-brain barrier in progressive multiple sclerosis more than in other forms (176). The type of inflammation may differ or tight junctions may be compromised because fibrin is increased in the perivascular space in chronic plaques. Many active demyelinating lesions are missed on MRI, suggesting there is a spectrum from profound inflammation in classical plaques, to moderate T cell inflammation in slowly expanding plaques, to mild or no inflammation in inactive plaques (171).

Adhesion molecules on T cells bind ligands on endothelial cells. Bound T cells then penetrate directly through the endothelial cells (emperipolesis), not necessarily through the tight junctions (12). The self-amplifying loop between activated T cells and activated endothelial cells is blocked by natalizumab and by interferon. After monocytes cross through endothelial cells of the blood-brain barrier, they pile up in the perivascular space. The glia limitans outside the basement membrane or basal lamina is then breeched by matrix metalloproteases. Their secretion is diminished by IFN-beta therapy. The combination of natalizumab and IFN-beta could synergistically decrease leukocyte traffic into the CNS.

Cell penetration of the blood-brain barrier

Penetration of the blood-brain barrier is a 2-step process. First, emperipolesis through endothelial cells (blocked by natalizumab and possibly interferon) or penetration through the tight junctions after digestion by matrix metal...

The initial inflammatory lesion is a cuff of macrophages and CD4 T lymphocytes that surround vessels lined with activated endothelial cells expressing major histocompatibility complex class II proteins (319; 257), similar to the lesions of experimental allergic encephalomyelitis. Very early, the lesion margin may be indistinct (257). Sensitive magnetization transfer ratio MRI scans can detect abnormalities weeks prior to Gd+ enhancement. Cellular infiltration is minimal in some acute plaques, suggesting a direct insult to oligodendrocytes, similar to the Lucchinetti type III lesions (24). Clusters of 4 to 50 HLA-DR+ microglia in normal-appearing white matter, microglia nodules, can precede new lesions. These authors argue that in some early cases, oligodendroglial damage precedes immune infiltration; then macrophages arrive, followed by T cells, suggesting that multiple sclerosis is a primary degenerative disorder (debated). In another study of very early plaques, there were clusters of activated microglia, a few CD8 > CD4 cells, activated complement (not on myelin), and mild to moderate demyelination, all near Virchow-Robin spaces filled with CD4 and B cells (112).

The extravascular Virchow-Robin spaces are dilated in multiple sclerosis. These spaces drain into the CNS glymphatic system, then to leptomeninges and cervical lymph nodes where CNS antigens may provoke anti-brain immunity. Drainage is enhanced by pulsatile norepinephrine-induced contractions but declines with aging. Low glymphatic drainage is associated with worse Parkinson symptoms and cognitive impairment in pediatric multiple sclerosis.

Dendritic cells from inflammatory CNS sites also migrate and join with lymphatic endothelial cells in the olfactory cribriform plate. In this site, immune cells secrete immunosuppressive cytokines.

Acute plaques typically spread out from post-capillary venules. Cytolytic CD8 cells damage neurites, axons, and oligodendroglia. Clonally expanded (“oligoclonal”) CD8 cells begin to outnumber CD4 cells at the plaque margins (39; 14). These margins are often abrupt, suggesting a battle between the spread of inflammation and endogenous resistance to the intruders. CNS “immune privilege” may contribute to the immune cloaking of brain cells. Therapy benefit differs between regions. “High efficacy” therapy is better than moderate efficacy therapy at reducing new brain lesions, but cord lesions occur at the same rates with both categories of therapy (164).

Neurons express immune-inhibitory transforming growth factor-beta. Neuron-T cell contact converts encephalitogenic CD4 T cells to regulatory CD4 T cells that inhibit experimental allergic encephalomyelitis (182).

Gray matter contains myelinated fibers. Although cortical T2 lesions are rare on conventional MRI, demyelination can be extensive. There is neuronal and synaptic loss in the cerebral cortex and death in up to 35% of thalamic neurons (56). Cortical atrophy correlates with fatigue (frontal cortex), cognitive loss, and physical disability. “Myelocortical disease” affects cerebral cortex and spinal cord but largely spares white matter (318). Atrophic deep gray matter (thalamus, putamen, caudate) has reduced blood flow (See CCSVI). Thalamic neurodegeneration is more prominent than demyelination (193). Extensive neuronal loss in the hypothalamus is common (135) and may explain disruption of circadian rhythm, cortisol regulation, sexual function, depression, weight control, and even sleep (143). Forty percent of cortical neurons show synaptic loss after 30 years of disease. Spinal cords are even more affected, with synaptic loss in 60% to 95% and anterior horn cell loss in 50% (242), likely the cause of thoracic paraspinous muscle atrophy. Cortical and thalamic atrophy are correlated but independent of cord atrophy.

Cortical lesions vary in morphology: contiguous with expanding subcortical lesions (cortical type I), confined to small perivascular areas of the cortex (type II), or extend from pia to cortical layer 3 or 4 (type III) (241). These multiple sclerosis-specific, subpial lesions appear in cerebellum, hippocampus, and deep invaginations, targeting the cortex of the insula, cingulate, and deep occiput and frontal and temporal-basal areas (171). Cortical plaques compromise 60% of all brain lesions but are missed on histopathology when the usual long-duration Luxol Fast Blue destaining is used to detect centrum semiovale white matter demyelination. Type I cortical lesions in later multiple sclerosis are linked to cognitive loss and white matter loss, perhaps from disruption of U fibers and intracortical communication. Type II cortical lesions in early multiple sclerosis correlate with physical disability. Type III subpial lesions, usually in chronic, progressive disease, suggest “outside in” damage under the inflamed meninges due to soluble factors (225).

Cortical lesions are much less inflammatory than white matter lesions. There are 10- to 20-fold fewer T cells and 6-fold fewer macrophages and microglia, less complement activation, less blood-brain barrier breakdown, and minimal edema compared to white matter plaques. This parallels their lack of MRI enhancement. Despite fewer invading immune cells, activated microglia ensheathe cortical neurites and apoptotic neurons. Neuronal gray matter breakdown markers are higher in CSF from first attacks than in later stages (288), suggesting very early damage of neurons.

Lymphoid germinal center-like B cell clusters in the meninges, over the surface of the brain, are associated with cortical lesions. Supernatant from multiple sclerosis B cell cultures is toxic to oligodendrocytes; the toxin is not immunoglobulin. Type 1 cortical lesions have less GAP43 protein, indicating that atrophic cortex has lost neurons (approximately 10% fewer) and glia (36%). Nonetheless, repair is more efficient in cortical than white matter lesions (52). Myelin sheaths reappear in 71% of subpial lesions, astrocytosis is decreased, and there are normal numbers of oligodendrocyte progenitor cells.

Oligodendrocytes are the major target in multiple sclerosis. One oligodendrocyte maintains myelin on 50 axons and contributes to neuron and axon survival. This support has an extraordinary metabolic demand. Oligos are easily damaged yet contain plentiful protective mechanisms and can remyelinate. In cultures of stressed adult, but not fetal, oligodendroglia, the Antel lab finds myelin changes precede cell body death, including degeneration of the inner cytoplasmic tongue and bleb formation (67). The mRNA binding proteins, TDP-43 and PTB (polypyrimidine tract binding protein), are mislocalized in oligodendrocytes, likely affecting alternative splicing of RNA and altering production of multiple myelin proteins (202). The myelin-axon interaction is impaired in early multiple sclerosis plaques; later, oligodendrocytes are often apoptotic with associated demyelination, gliosis, and microglial activation. Axonal damage depends on the type of inflammation, size of lesion, and ability to repair. Oligodendrocyte progenitor cells (OPC) are numerous, widely distributed, and can differentiate to remyelinate naked axons, along with surviving mature oligodendrocytes. Possibly related, the myelin sheath is stochastically built by homotypic fusion of myelin membranes at the front of an oligodendrocyte process (307).

Monocytes and macrophages destroy neurons and oligodendroglia; their proportion in lesions increases in later stages of multiple sclerosis. Nearly half of the macrophage-like cells in active lesions are resident yolk-sac-derived TMEM119+ microglia; the other half are recruited from the peripheral blood. Oligodendrocyte loss correlates with the number of macrophages but not with T cells or plasma cells (186). CD8 T cells, NK cells, and gamma/delta T cells also damage oligodendrocytes through the NKG2D protein and other molecules. Gamma/delta T cells in multiple sclerosis CSF secrete slightly more IL-17 than nonmultiple sclerosis cells. CD4 cells do not directly damage oligodendrocytes but do secrete cytokines that activate CNS-damaging CD8 cells and macrophages.

Monocytes and microglia activate NOS and also cause lipid peroxidation, tyrosine nitrosylation, and DNA strand breaks (354). Macrophages and microglia release IL-1, which then induces glutamate to cause synaptic hyperexcitability and death of neurons and a fall in neuronal N-acetyl-aspartate (NAA). Glutamate is also toxic to oligodendroglia. Within active lesions next to dystrophic axons, macrophages express high levels of glutaminase involved in glutamate synthesis (343). CSF IL-1beta levels correlate with number of MRI lesions and with poor prognosis. Potentially enhancing damage, IFN-beta blocks secretion of anti-inflammatory IL-10 in activated macrophages and likely in microglia, contrary to its effect in the periphery where it increases T cell IL-10 (96). This suggests therapy, perhaps combination therapy, could be tailored to the inflammatory makeup of the brain in different forms of multiple sclerosis.

Partial remyelination during recovery from relapse is common in early multiple sclerosis as well as in progressive disease (240). Repaired fibers are thinly myelinated within acute plaques or at the edge of chronic plaques during and after active myelin breakdown. Remyelination is more extensive in the cortex than in the white matter (03). Moderate remyelination by hyperplastic oligodendroglia sometimes forms a "shadow plaque" with severe demyelination in the center but thin myelin sheaths in the shadowy periphery of the plaque (250). Importantly, few MRI studies measure the density of demyelination and repair, “shades of gray,” in T1 black holes.

Multiple sclerosis plaque (MRI)

T2-weighted MRI showing multiple sclerosis plaque with concentric differences in intensity. These are likely to be lesions of different duration, surrounding the same post-capillary venule. (Contributed by Dr. Anthony Reder.)

Gliotrophic factors and cytokines secreted by lymphocytes and some macrophages enhance remyelination. Low levels of inflammatory cytokines can trigger protective oligodendroglial genes, such as HIF-1alpha and HSP70; oligodendrocytes also produce growth factors, NGF, IGF-1, and TGF-beta (354). N-acetyl-aspartate (NAA), synthesized in neuronal mitochondria, is reduced in lesions. As the brain recovers, N-acetylaspartate in plaques increases in parallel with better clinical outcome (223; 55), suggesting that formerly compromised neurons are now healthy.

Oligodendroglia precursor cells (OPC), expressing the anti-apoptotic protein Bcl-2, arise in the plaque or migrate into demyelinated lesions from the subventricular zone. In white matter plaque subtypes I and II (187), oligo precursors are preserved and remyelinate axons. Macrophage products, plus IL-11, chemokine CXCL2, platelet-derived growth factor (PDGF), and fibroblast growth factor-2 (FGF-2), increase the number of oligodendroglia precursor cells. Clemastine (often clinically intolerable) and muscarinic M1 receptor antagonists stimulate oligodendroglia precursor cell differentiation and remyelination, as does ketoconazole, which modifies cholesterol synthesis and increases sterols. Opposing repair, fibroblast growth factor enhances oligodendroglia precursor cell recruitment but inhibits differentiation. Myelin basic protein inhibits oligodendroglia precursor cell differentiation; IFN-gamma inhibits remyelination. (See “Recovery from relapses,” above.)

Perineuronal oligodendrocytes are nonmyelinating progeny of oligodendroglia precursor cells with a unique membrane and RNA profile (308). These cortical cells support neurons and protect themselves and neurons from apoptosis. They do respond to oligo-preserving therapies used in multiple sclerosis and amyotrophic lateral sclerosis.

There are few mature oligodendrocytes and surprisingly little remyelination of adjacent bare axons despite the presence of premyelinating oligodendrocyte precursors in chronic plaques [see (19)] (53). Loss of axonal receptivity for remyelination and lack of remyelination could be from multiple factors:

	• Immune cells and inflammatory cytokines persist in lesions and impair oligodendrocyte and neuronal function.
	• Interferon-gamma and the endoplasmic reticulum stress response to unfolded proteins, at low levels, protects mature oligodendrocytes. However, an excessive stress response in multiple sclerosis causes death of active remyelinating oligos.
	• Inflammation has toxic effects on membrane clusters of sodium channels at the bare axonal paranode.
	• Demyelination disrupts the complex architecture of the paranode, interfering with repair.
	• Insulin-like growth factor, and its opponent IGF-binding protein, is increased on oligodendroglia in plaques.
	• Neuregulin decreases myelin formation and cannot aid remyelination.
	• With age, decreased histone deacetylase (HDAC) slows remyelination. HDAC is a potential drug target in multiple sclerosis (183).
	• In plaques lacking remyelination, activated astrocytes express Jagged1, a ligand for oligodendroglial Notch1 proteins (146). Notch inhibits oligodendrocyte maturation and process outgrowth, preventing remyelination (see CADASIL).
	• Other inhibitors of oligodendrocyte differentiation and remyelination include myelin-associated glycoprotein (MAG), oligo-myelin glycoprotein (OMgp), Netrin-1, Nogo, and Nogo receptor-interacting protein (LINGO-1), plus chondroitin sulfate proteoglycans and hyaluronan. Serum and CSF Nogo-A is elevated in relapsing and progressive multiple sclerosis (147). NOGO-B, however, enhances immune response to double-stranded RNA, linking the NOGO family to antiviral responses. Nerve growth factor induces LINGO on oligos and axons. Several agents encourage oligodendroglial irredentism in plaques. Therapy with anti-LINGO antibodies and siRNA promotes oligodendroglia precursor cell differentiation and enhances remyelination (210). M1 muscarinic antagonists reverse negative regulation of myelination. Both have slight effects on optic nerve repair in human trials.

With each CNS insult, and continuously during chronic multiple sclerosis, oligodendrocyte precursors and mature cells die, and remyelination falters. With chronic progressive disease, normal-appearing white matter shows diffuse loss of myelin, infiltration of T cells, and microglial activation (171). Reactive oxygen species, glutamate, proteases, viruses, and immune cell products (nitric oxide, IL-1-beta, and tumor necrosis factor-alpha) damage myelin. IFN-gamma protects mature oligos against oxidative stress but damages immature oligos (17). Loss of trophic support from compromised oligodendroglia and disrupted myelin will damage axons, even in the absence of inflammation. Nonetheless, some patients remyelinate, trumping the effects of inflammation and age. Some shadow plaques show extensive remyelination, even in elderly patients with long-standing disease (240).

Axons are damaged in multiple sclerosis. During the earliest stages, there are abundant axonal “ovoids,” ends of transected axons ballooning from ongoing anterograde transport (Charcot 1850; 316). There are 10,000 axonal spheroids/mm3 in multiple sclerosis plaques (transected days or years earlier), but only 2/mm3 in healthy controls. Early active lesions have 10% to 20% axonal loss. Even in normal-appearing white matter, axons are half as numerous as in control brains. In chronic progressive multiple sclerosis, one half of the axons in many long tracts and the corpus callosum disappear (36). Unexpectedly, there is little correlation between plaque load and axonal loss, suggesting there are different types of repair and inflammation. The atrophy rate on MRI in untreated multiple sclerosis is approximately 1% per year--higher than in healthy controls (0.12%) but less than in Alzheimer disease (3%).

Axonal damage predominates in the optic nerve, corpus callosum, and spinal cord and correlates with clinical disability and with central nervous system atrophy (316). In the cervical cord, up to 65% of the axons can be lost. In the corpus callosum, transcallosal bands of Wallerian degeneration predict poor prognosis. The damage predominates in small-sized axons, in sensory axons in the cervical spinal cord, and in corticospinal axons at all levels (74). Axonal loss is reflected in elevated CSF neurofilament light chain protein, Wallerian degeneration and low magnetization transfer ratio on MRI, and decreased N-acetyl aspartate (NAA) on MR spectroscopy.

Acute axonal damage is worst in the first year of disease activity and correlates with the number of CD8 T cells, monocytes, and activated microglia in plaques (165). Cytotoxic CD8 cells attach to dendrites and axons and transect them by releasing perforin. Monocytes release nitric oxide and glutamate--also toxic to neurons. Myelin-specific CD8 cells are more frequent in relapsing than in progressive multiple sclerosis. Amyloid precursor protein, reflecting acute damage to neurons days to weeks after the insult, predominates in acute early multiple sclerosis and in edges of chronic active plaques in secondary progressive disease (35). Amyloid precursor protein levels correlate with the presence of monocytes and CD8 cells but not with CD4 cells.

Circulating antiganglioside antibodies in progressive multiple sclerosis reflect axonal damage. Antibodies generally bind to axons but not to myelin. They are present in 50% of primary or secondary progressive patients compared to only 3% of relapsing-remitting patients (277). T cells proliferate to GM3 and GQ1b in primary progressive disease. Demyelination and toxic cytokines increase the energy demand of impulse conduction.

As inflammation subsides, axonal sodium channels redistribute out from the nodes of Ranvier into demyelinated regions. Greater Na+ influx is accompanied by a greater Ca++ influx (one tenth of the Na+ flux), so compromised axons must contend with sequestration of potentially toxic Ca++ (276). Axonal mitochondria are dysfunctional, also leading to calcium-mediated axonal degeneration. Low axonal ATP is akin to a state of chronic hypoxia with mitochondrial dysfunction, and high Na+ and Ca++ influx (317). An insightful patient said her brain and immune system were both “tired.”

Altered ion channels affect neuronal function. Ten subtypes of sodium channels control timing and duration of axon potentials. A channelopathy can arise when new types of sodium channels appear at high density in demyelinated axons (340). There is also robust expression of sodium channels on activated microglia and monocytes. Blockade of Na channels with phenytoin decreases inflammation (64), and phenytoin and flecainide inhibit experimental allergic encephalomyelitis. Abrupt withdrawal of phenytoin or carbamazepine provokes exacerbation of experimental allergic encephalomyelitis, though this is not reported in multiple sclerosis. Lamotrigine, a Na+ channel blocker directed at immune cells and naked axons, slightly enhanced walking speed in multiple sclerosis but was linked to more brain atrophy (152).

The central nervous system is normally hostile to immune activation (“immune privilege”). Reflecting this, brain tumors that produce inhibitory cytokines are more aggressive (344). The blood-brain barrier prevents access of white blood cells and cytokines to the normal brain because of tight junctions, few lymphocyte adhesion molecules on endothelial cells, minimal endothelial transcytosis, and potent extrinsic pumps (PgP) and active transporters. Glia secrete transforming growth factor-beta, platelet-derived growth factor, and prostaglandin E, which inhibit lymphocyte proliferation (270).

Immune privilege of the brain can be subverted. Myelin basic protein, tau, neurofilaments, and 14-3-3 proteins in CSF reflect neuronal and glial damage. CNS antigens drain into brain lymphatics (249), exiting not through the nasal cribriform plate but through arachnoid granulations, emptying into dural sinuses and then into the deep cervical lymphatics (259). Brain antigens in cervical lymph nodes promote B cell maturation, provoke strong antibody responses, and educate Th1 cells, but also enhance regulatory Th2 immunity. Immune privilege can be lost in multiple sclerosis lesions, perhaps by cells educated in the cervical lymph nodes without normal regulatory control, which rapidly return to the CNS.

The Virchow-Robin spaces in the brain contain extracellular matrix proteins, facilitating migration of MHC-expressing macrophages that interact with T and B cells. In chronic plaques, astrocytes hypertrophy and express costimulatory B7-1 and B7-2 molecules plus MHC class I and II proteins, possibly allowing them to present antigens. B cells also act as antigen-presenting cells, co-stimulate T cells, and secrete cytokines (114; 65).

Antibodies are produced within the CNS itself. B cells in the CNS undergo local clonal expansion, activation, “receptor editing,” and hypermutation and so develop an activated memory cell phenotype (216). Immunoglobulin from these few clones forms an oligoclonal band pattern. Editing of surface immunoglobulin in response to antigens improves affinity but ordinarily reduces any proclivity to autoimmune disease. B cells recognize their cognate target in its native form; T cells recognize degraded antigen presented by myeloid cells. Initially “nonsense antibodies” with no detectable targets were described in CSF (205). Concentrated CSF and supernatants of B-cell clones often react to Epstein-Barr virus proteins but also to many other viruses (87). Overall, a disease-inciting antigen has not been identified in multiple sclerosis.

Germinal center-like areas, resembling those in the spleen and lymph nodes, appear in the perivascular spaces of some old multiple sclerosis plaques (249) and in the meninges, largely restricted to secondary progressive multiple sclerosis. Similar structures are seen in affected tissues in rheumatoid arthritis, Sjögren syndrome, Crohn disease, Hashimoto thyroiditis, and in female dogs with granulomatous meningoencephalomyelitis. This organized inflammation appears in the meninges, often in sulci, in 40% to 54% of autopsy cases. Germinal center-like areas in the meninges contain follicular dendritic cells, plasma cells, and proliferating B cells (290). B cells and myeloid cells produce cytokines that drive growth of these tertiary lymphoid tissues. For instance, TNF-alpha induces B cells to proliferate and form germinal center-like areas. Lymphotoxin-alpha, essential in formation of tertiary lymphoid structures, is elevated in multiple sclerosis CSF. These ectopic B cell follicles can be sites of Epstein-Barr virus persistence, possibly driving antibody production detectable in CSF (289). An alternate explanation for these germinal center-like areas is that CNS injury itself or unknown antigens trigger autoimmunity and local B cell activation (09). The B cell follicle-like areas are associated with subpial microglial activation, demyelination, and cortical atrophy. T cells that control B-cell function are present in spinal meninges and near activated microglia in the normal-appearing white matter of the spinal cord. Axonal density in the cervical cord of patients with progressive multiple sclerosis is 25% less than in controls, and T cells in the meninges correlate with the atrophy (08). Some multiple sclerosis therapies have difficulty reaching parenchymal and meningeal sites.

As the plaque ages, its inflammation and edema partially resolve, and the immune cell composition changes. The relative number of B cells, CD8 cells, and monocytes increases; CD4 cells decrease (39; 173). The margins of chronic inactive plaques have fewer inflammatory cells, but CD8 cells are 10 times more numerous than CD4 T cells. There are also myelin-laden macrophages, occasional plasma cells and mast cells, a glial scar, and damaged and demyelinated axons. In late chronic plaques, inflammation is minimal and comparable to other neurologic disease controls. Antiviral CD8 cytolytic cells persist in the CNS long after the virus disappears. Perhaps an inciting agent is missing in adult plaques, but its legacy remains.

Mast cells are typically missed by usual histological stains, but they are visible in chronic active lesions with specific stains (137). Mast cells may be a consequence of any kind of chronic inflammation and are not specific to multiple sclerosis. Mast cells encourage immune cell migration through the blood-brain barrier, activate Th1 cells, and release destructive molecules. Opposing these effects, mast cells could secrete neuroprotective molecules and induce IL-10+ regulatory B cells; mast cell histamine also induces Th2 cells and myeloid suppressor cells. On microarrays of mast cells, there is high expression of mRNA for “allergic” molecules, such as prostaglandin D synthase, histamine receptors, immunoglobulin Fc-epsilon receptor, tryptase, and chemokine CCL5, stem cell factor (63). BTK inhibitors and masitinib therapy affect mast cells. Mast cells contain large amounts of N-acetylaspartic acid, which may be confounded with neuronal N-acetylaspartic acid on magnetic resonance spectroscopy, potentially important in evaluating these therapies.

RNA profiles differ between multiple sclerosis plaques and normal white matter. The signature is of neuroprotection, anti-oxidative stress (inflammatory and anti-inflammatory), and mitochondrial deactivation, with nearby glial and astrocytic activation. This lesion profile suggests ongoing efforts to repair lesions. Proteomic analysis shows activation of tissue factor and other coagulation molecules. Heterogeneity of lesion activity, varying damage, a mix of cells, and the varied age of subjects illustrates the complexity of the disease.

Brain pathology in multiple sclerosis is not stereotypical. MRI images range from small lesions in white matter to huge plaques that are sometimes mistaken for gliomas. Large solitary demyelinating lesions in the centrum semiovale, even if associated with multiple plaques, sometimes have good prognosis (157). Brain pathology differs between primary progressive and relapsing-remitting multiple sclerosis. In primary progressive disease, spinal cord lesions predominate and cause gradual paraparesis. There are fewer Gd-enhancing lesions in white matter, but brain myelin is pale (“dirty” MRI) in the white matter. Cortical atrophy and demyelinated plaques in deep gyri of the cerebral cortex, insula, cingulate, limbic circuit, and cerebellar cortex are much more severe than in relapsing-remitting multiple sclerosis (172). The damaged area of cortex is 4-fold greater in secondary and primary progressive than in relapsing/remitting multiple sclerosis. Subpial germinal center-like areas may contribute to cortical damage. In Alzheimer disease, beta-amyloid deposition increases near sulci, suggesting CSF flow plus deep germinal center-like areas may affect the cortex. However, beta-amyloid levels are low in multiple sclerosis cortex, most in demyelinated areas. N-acetyl aspartate levels are low in the cortical gray matter, reflecting reduced neuronal function (285) and paralleling the high metabolic demand and aerobic glycolysis in lesions (44). Urine myelin basic protein-like material is lower than in secondary progressive multiple sclerosis, suggesting a slower rate of destruction in primary progressive disease. Extensive hippocampal demyelination in chronic multiple sclerosis interferes with cognition (115).

Lesions range from acute inflammation with blood-brain barrier disruption to slowly expanding (SEL) smoldering, to inactive, to repair with remyelinated shadow plaques, especially early on (99). Distinct lesion patterns in different brains, but similar within a given brain, appear in biopsies of large lesions and at autopsy (187). Pathological subtypes depend on the degree of inflammation, myelin destruction, and oligodendroglial preservation. In each case, macrophages outnumber T cells by 10-fold and T cells are 10-fold more numerous than B cells.

Four pathological subtypes are described by Lucchinetti, Lassmann, and Bruck.

Pathological subtypes of multiple sclerosis in brain

This table shows the four subtypes of multiple sclerosis pathology in the brain. (Contributed by Dr. Anthony Reder.)

I. T cell and macrophage-mediated demyelination (18% of 201 patients)
II. T cell and macrophage, plus antibody-induced or complement-mediated demyelination (56%), with antibodies bound to myelin
III. Oligodendrocyte dystrophy and apoptosis with myelin protein dysregulation (24%)
IV. Primary oligodendrocyte degeneration with features similar to viral, ischemic, or toxic oligodendrocyte damage (2%)

Patterns I and II are seen in acute, early multiple sclerosis. The intense perivenous immune reaction causes a sharply demarcated area of demyelination and destruction of oligodendroglia, astrocytes, and axons. Oligodendrocytes are preserved and there is significant remyelination (shadow plaque), without (pattern I) or with deposition of activated complement and IgG (pattern II). Many myelin proteins decrease, but myelin-associated glycoprotein is not lost. Oligodendrocytes die at the expanding plaque edge but can reappear in the remyelinating plaque center.

Patterns I and II show ring enhancement with a hypointense rim on T2 MRI. Pattern I resembles destruction of myelin by macrophage products (TNF-alpha and reactive oxygen species). Pattern II resembles experimental allergic encephalitis induced by myelin oligodendrocyte glycoprotein (MOG), mediated by T cells interacting with anti-MOG antibodies.

Antibody and complement-facilitated pattern II is the most common. They usually do not react with myelin antigens. Some antibodies, especially IgM, may stimulate remyelination; however, clinical trials failed. Others are probably pathogenic, ie, antibodies to gangliosides (above) and IgM against myelin and S-nitrosocysteine (from nitric oxide reactants, some directed against myelin-associated glycoprotein on oligodendrocytes) (40). Complement binding to antibodies increases the destruction. Nonetheless, myelin damage in pattern II appears to be macrophage-mediated, and some authors argue that immunoglobulin and complement deposition in multiple sclerosis tissue is a nonspecific feature (23). However, plasma exchange has benefit in pattern II but not in patterns I and III.

Patterns III and IV exhibit oligodendroglial dysfunction demyelination, and death. Pattern III consists of an inflammatory infiltrate of macrophages, microglia, and T cells but no immunoglobulin, with ill-defined, non-perivenous areas of demyelination (preservation of oligodendroglia near venules) and only limited remyelination. Concentric rings of demyelination are reminiscent of Balo concentric sclerosis, with “dying back” destruction and apoptosis of oligodendrocytes. In distal peri-axonal oligodendrocyte processes, there is a marked drop in myelin-associated glycoprotein, which is needed for myelin attachment to axons and possibly for remyelination (53). This pattern resembles acute white matter hypoxia and suggests a virus or toxin, such as nitric oxide, that interferes with mitochondrial energy production. One third of multiple sclerosis brains show actual cortical microvascular hypoxia on near-infrared spectroscopy.

Pattern IV consists of an inflammatory perivenous plaque with a sharp border of destruction and apoptotic loss of oligodendroglia with little remyelination. This rare pattern is seen only in primary progressive multiple sclerosis. It may reflect an underlying dysfunction in oligodendroglia (oligo-opathy) (123).

Patterns I, II, and III are seen in acute, relapsing-remitting, and secondary progressive multiple sclerosis. Patterns I, II, and IV are seen in progressive multiple sclerosis.

Active plaques throughout a given brain exhibit a similar histopathological subtype and similar pattern of MRI lesions, suggesting a consistent immune and brain response at the time of biopsy (187). Differences in pathology between patients suggest heterogeneity in disease pathogenesis, in the mechanism and targets of demyelination, and probably in therapeutic responses. Theoretically, agents that modify cellular immunity (eg, interferons) are best for subtype I. Plasmapheresis or intravenous immunoglobulin might be of benefit in antibody-mediated subgroup II. Surprisingly, anti-B-cell therapies benefit subtypes I and II, indicating this therapy has immune effects beyond the B-cell realm. Growth factors for oligodendroglial progenitors or actual oligo transplants are potential therapies for types III and IV. Nonetheless, there are no obvious subtype-specific responses to any multiple sclerosis therapy.

In a smaller series, different categories were combined in one brain, such as pattern IV in some plaques but other plaques with remyelination (ie, patterns I or II) (24). They suggest that oligodendroglial apoptosis may precede inflammation. In contrast, in late “established” multiple sclerosis, all lesions show complement and antibodies that are associated with macrophages in areas of active demyelination (42), suggesting that heterogeneity disappears over time.

More attention has turned to progression. Current therapies have only partial benefits on slowing progression, and the gene profiles between relapsing and progressive forms are very different (104). Progression independent of relapse activity (PIRA) is associated with more aggressive disease and with smoldering, slowly expanding lesions. PIRA increases in each decade after disease onset (1.3% at 20 years of age, 9% at 30, 22% at 40, 39% at 50, 61% at 60, and 77% at 70) (136). Early PIRA is associated with faster progression. PIRA is associated with age, duration of disease, higher relapse rate, and insufficient B-cell depletion with anti-CD20 therapy. In an early cohort, 28% had PIRA and 18% had relapse-associated worsening (RAW) (245), indicting that PIRA-associated worsening is more important than relapse-associated worsening (RAW) (153).

Imaging of histopathological subtypes, clinical symptoms, and therapy response. MRI reveals extent of brain and cord lesions, presence of new lesions, atrophy, and certain responses to therapy (171; 48). MRI T2 signal is from edema; T1 hypointensity is from axonal loss, myelin loss, edema, and widening of the extracellular space.

Endovascular and perivascular inflammation causes gadolinium-enhancing lesions. Small nodular lesions enhance from the center outward; ring-shaped lesions enhance centripetally over 30 minutes (110). Ring-enhancing lesions are areas of new inflammation, with a sharp border of macrophages that secrete TNF-alpha, some T cells, oligodendroglia with DNA fragmentation, and axonal loss. The ring surrounds older lesions and is characterized by protein leakage (blood-brain barrier breakdown), isointense T1, and hyperintense T2 MRI (45). Ring-enhancing lesions correspond to pattern I and II lesions described above. T2 activity persists after contrast enhancement resolves, reflecting degeneration and repair. Small T2 lesions are disproportionately more damaging than large ones (208). Demyelinated or remyelinating lesions have less inflammation and modest blood-brain barrier breakdown. They are hypointense on T1 (less so with remyelination) and hyperintense on T2 and are variably enhancing (45).

A central vein is visible in over 90% of new and old T2 lesions on susceptibility-based MRI, illustrating attachment then egress of immune cells through endothelial cells of postcapillary venules followed over weeks by tissue remodeling of the vessel wall, enlargement of the lumen, and perivenular collagen-I deposition (01). Central vein lesions are more common in multiple sclerosis than in other inflammatory brain diseases.

Smoldering areas of inflammation and iron deposition surround the plaques and form a slowly expanding (SEL) paramagnetic ring/rim lesion (PRL) on susceptibility-based MRI. This rim of iron-laden macrophages/microglia expresses co-stimulation markers CD40 and CD86 but also immune suppressive CD163 and iNOS. It remains active after the acute lesion subsides. At least one paramagnetic rim lesion appears in 50% of relapsing and 60% of progressive multiple sclerosis cases but in only 7% of other inflammatory brain diseases (191; 48) These lesions are detectable during treatment, and they correlate with worse and accelerated disability. They reflect innate immunity and unfolded protein response, coinciding with reduced repair capability (104). PRL are reduced by BTK inhibitors and anti-CD20 therapy. All therapies have some benefit, but average progression is slower by anti-CD20 and natalizumab than interferons and glatiramer.

MRI is a dramatic way to demonstrate CNS lesions to patients, but there are caveats for using MRI lesions as a biological marker for multiple sclerosis. The T2 edema signal alone can’t differentiate between demyelinated and partially myelinated lesions. Two of nine T2 MRI lesions show no demyelination on postmortem analysis (22). Lesions in many parts of the brain are clinically silent. Correlation between T2 lesions and clinical symptoms is poor (r = 0.2 to 0.3; less than 6% of the variance) (“clinical-tomographic or clinical-MRI dissociation”). In 1354 placebo-treated relapsing-remitting patients from 45 clinical trials and natural history databases, T2 total lesion load did not predict change in disability from baseline to trials’ end (68). There was a small predictive effect of total lesion load on disability in secondary progressive multiple sclerosis (r = 0.21). Gd+ lesions did not predict clinical relapses. In contrast, T1 black holes measure lost axons, and correlate well with spinal cord atrophy and with clinical deterioration in secondary progressive multiple sclerosis (r = 0.8) (21), but not in relapsing-remitting multiple sclerosis (r = 0.3) (298). Eighty percent of T1 black holes are demyelinated, but in “T2 only” lesions, merely 20% of plaques are demyelinated (215). Glatiramer acetate and IFN-beta reduce the chance that black holes will become permanent (100), and both therapies prevent black holes ab initio.

Gd+ lesions are most common early in the course of multiple sclerosis and in relapsing compared to primary progressive disease. Multiple new and reactivated Gd+ lesions appear in concert during disease activity. In a cohort of untreated patients with Gd-positive scans, the number of contrast-enhancing lesions falls at 3 months by 4%, at 6 months by 29%, and at 9 months by 48% (355). Occasional T2 lesions arise without enhancement, especially in periventricular areas (175). Long-duration Gd+ lesions are most likely to evolve into a hypointense T1 lesion. Two or more Gd+ lesions strongly predict the development of multiple sclerosis (96%) after an isolated clinical attack (Group CHAMPS 2002). However, Gd-enhancing lesions are only modest predictors of a worse clinical course. Changes in therapy must be made in the context of clinical patterns and not simply based on Gd+ lesions.

Brain regions differ in Gd enhancement. Cortical gray matter lesions are difficult to see on T2-weighted MRI but are sometimes seen with FLAIR and are more easily seen with an 8 Tesla magnet (16). Double inversion recovery MRI is more sensitive and detects cortical lesions in over 80% of primary progressive multiple sclerosis brains (49). Immune responses and edema in gray matter are reduced due to less myelin, little water, and 10 times fewer inflammatory cells than in white matter lesions (241). This may explain why plaques enhance in the white matter but do not extend into the gray matter on T1 MRI, forming an “open ring” that is highly specific for a demyelinating lesion. Importantly, subcortical U fibers often form a dark band between the cortical gray and the underlying white matter lesion on T2 or FLAIR MRI, perhaps because of higher iron content or different cell composition. This appearance helps differentiate an MS lesion from an infarct. Even with minimal visible inflammation, cortical neurons are injured, contributing to motor, sensory, and cognitive losses and fatigue.

Lesion location determines clinical symptoms, although patients with “benign multiple sclerosis” can have brain atrophy and N-acetyl aspartate content similar to those with severe disability. Disabled patients often have atrophy at the second cervical cord segment (41). Some patients with primary progressive multiple sclerosis have only diffuse MRI abnormalities in brain and cord (“dirty white matter”) (357), reflecting widespread inflammation and significant axonal pathology.

Functional MRI measures blood flow to brain areas involved in a task. Myelin speeds axonal impulses and is more than simple insulation. Myelin controls timing of information flow and organizes network connections. Abnormal activation of wide areas of primary cortex and supplementary motor cortex is seen even in very early multiple sclerosis, indicating disruption of neural networks. The enlarged area of cortical activity on fMRI is presumably less efficient because plaques and demyelination have disrupted normal connections, forcing cortical reorganization or use of less efficient latent pathways.

The rate of brain atrophy on MRI is up to 10-fold faster than normal in progressive multiple sclerosis. In early relapsing-remitting multiple sclerosis, gray matter atrophies at twice the rate of normal controls (314). Atrophy is caused by loss of neurons and axons, and damaged oligodendroglia and myelin. Atrophy measures are variable and difficult to apply to individual patients. Dehydration for 16 hours shrinks brain volume by 0.55% and can confound measurement of atrophy. Studies do not account for diuretic effects of interferons and other drugs. Gd+ lesions often do not predict brain atrophy (281) but do predict future atrophy when they are ring-enhancing with central contrast pallor (177) and when they are present at onset of multiple sclerosis (298).

Gray matter atrophies in cortex (especially in deep sulci), thalamus (especially adjacent to the third ventricle), and hippocampus (CA1 and subiculum). Hippocampal volume loss is associated with high cortisol and depression in multiple sclerosis. Of note, in Alzheimer disease, cortical amyloid deposits are high near deep sulci. Deep gray atrophy also correlates with slowed cognition. The intercaudate nucleus distance correlates with loss of clinical function (brain atrophy versus disability, r = 0.67; versus cognitive function, r = -0.42). T2 lesions do not predict cord atrophy (29). Cord atrophy correlates best with clinical disability and poor walking. Serum cholesterol increases by 4.4% for each gadolinium-enhancing MRI lesion, demonstrating the role of comorbidities (236). Cigarette smoking is linked to lower brain volume and faster progression (83). Atrophy is slowed by some multiple sclerosis therapies.

Magnetic resonance spectroscopy detects constituents of neurons and glial cells. N-acetylaspartate is part of an osmoregulatory molecular water pump (25) that reflects neuronal and axonal function but not necessarily neuronal loss. N-acetylaspartate is also present in oligodendroglia. Concentrations are very high in mast cells, which could confuse magnetic resonance spectroscopy measures of presumed neuron and axon integrity. Early in multiple sclerosis, N-acetylaspartate is decreased in “normal-appearing white matter” and thalamic and cortical gray matter (98). Reduced N-acetylaspartate correlates with the number of clinical relapses over the preceding 2 years (239), suggesting that it forecasts prognosis even before T2 lesions and atrophy are visible. Loss of N-acetyl aspartate strongly correlates with fatigue, lateralized cognitive dysfunction, abnormal visual evoked potentials, and disability (36). Low cortical N-acetyl aspartate levels correlate with disability in primary progressive multiple sclerosis (285). Periventricular N-acetylaspartate is lowest in secondary progressive multiple sclerosis (204). Levels continue to fall in untreated patients but rise back toward normal after 6 months of IFN-beta therapy (223), indicating that metabolic disturbances in oligodendroglia, neurons, axons, and perhaps mast cells may be reversible.

MRI using ultra-small particles of iron oxide (USPIO) traces macrophage activity and labels oligodendrocyte progenitor and hematopoietic stem cells. PET scans of benzodiazepine receptor-labeled microglia (with PK1195) show lesions that are not detectable on regular MRI (20) and which are excessive in thalami and normal-appearing white matter in secondary progressive disease.

Cytokines, chemokines, autoantibodies, and Th1/Th2/monocyte ratios vary between patients and over time, possibly explaining some of the differences in disease course, pathology, or MRI lesions (131). Correlation of immune function, urine myelin basic protein (345), and MRI subtypes versus clinical responses in drug trials could determine prognosis or the best drug therapy.

Epidemiology

The prevalence of multiple sclerosis in the United States was estimated at 250,000 to 350,000 30 years ago (07), revised to 400,000 in 2007 to account for population growth, and revised again to 730,000 by the U.S. National Multiple Sclerosis Society in 2019 based on large datasets from 2010 (335). The prevalence is now 309 cases per 100,000 people, or 1 in 323. World prevalence was estimated at 1.25 million (73) and revised to 3 million. The incidence was 3.2 per 100,000 cases a year in the United States in the 1990s (142), 4.2 in the U.S. in 2007, and 7.5 in Olmsted County, Minnesota, the nidus of the Mayo Clinic (206). Higher prevalence is from slightly better reporting and from longer lifespan for patients and is now highest in those 55 to 64 years old.

The total number of cases in other locales is clearly increasing, although it appears to have plateaued in some high-prevalence areas (206). In Olmsted County, prevalence quintupled and the incidence quadrupled in the past 70 years (347). In Canada, the increase is largely in females (229). Over the past 4 decades, the ratio of females to males with multiple sclerosis increased from 2:1 to 3.5:1. The prevalence of multiple sclerosis has increased in regions of Scotland, Finland, Norway, Lower Saxony, Sardinia, Italy, Sicily, and the French West Indies (167). Allergy, Crohn disease, and type I diabetes show similar geographical distribution and increasing incidence. The increase has been attributed to altered immune regulation as exposure to infectious diseases has diminished, as well as different environments, migration to urban areas, and less sun exposure.

Geographical variation in the prevalence of multiple sclerosis is striking. Multiple sclerosis is rare in equatorial countries and becomes more common with distance from the equator in either hemisphere. Differences in prevalence are partially due to Northern European, especially Scandinavian, ancestry in affected populations, but there is also an environmental influence (231). Incidence is high (greater than 30 in 100,000) in northern Europe from Iceland to Russia, and in Canada, New Zealand, and southern Australia. Incidence is moderate (5 to 29 in 100,000) in the Mediterranean basin, the southern United States, and southern South America. Incidence is low (less than 5 in 100,000) in East Asia, India, Africa, the Caribbean, Central America, Mexico (especially in Indians and mestizos), and northern South America (166; 169; 252). In the United States, early studies showed northern areas had a prevalence of over 100 per 100,000 but only 20 per 100,000 in southern states. This gradient has attenuated over time.

Is the cause of multiple sclerosis genetic or environmental? Migration, ethnic, and twin studies indicate that genes and environment influence the development of multiple sclerosis. Northern European and Scandinavian ancestry is strongly correlated with multiple sclerosis risk (Pearson product-moment correlation = 0.5). English ancestry is negatively correlated in the United States (-0.5) (231). The prevalence in England was 42 to 80 per 100,000 fifty years ago (166). Israeli Jews have a prevalence of up to 62 per 100,000, but rates are lower in Christians (35 per 100,000), Moslem Arabs (15), Druze (11), and Bedouins (17) (04). Genetically similar immigrants have half the rate of native-born Jews, suggesting an environmental factor. There is a low incidence of multiple sclerosis in Gypsies, Asians, and native Black Africans. Black Americans of African ancestry (often racially mixed) born anywhere in the United States have a relatively high risk compared to native Africans. Decades ago, Blacks had half the rate of Whites in the United States (168), but in 2010 in Southern California, the incidence of newly diagnosed multiple sclerosis was 10 per 100,00 person-years in Blacks, 6.9 in Whites, 2.9 in Hispanics, and 1.4 in Asians (170). The main change was from the high rate in Black women. The average age of onset was later, 42 years, suggesting this cohort differs from many others. Blacks are more likely to have optico-spinal symptoms (and possible misdiagnosis of neuromyelitis optica), larger MRI lesion volumes, and faster disease progression than Whites. In contrast, people of Japanese ancestry in the United States have low rates of multiple sclerosis (76), but much or all of the association disappears when covariates such as socioeconomic status are excluded (199).

Genetic influences. A genetic component to multiple sclerosis is clear from twin studies. The monozygotic twin concordance rate is 31% (200 times background), the dizygotic rate is 5% after 7.5 years of observation (278), and the sibling risk is 3.5%. First-degree relatives have a 25-fold, and monozygotic twins a 300-fold, increased risk of developing multiple sclerosis compared to the general population (132). Another family member has multiple sclerosis 20% of the time. When both parents are affected, 9% of the children develop multiple sclerosis. In theory, the highest-risk monozygotic twin has an affected parent and a twin sister with multiple sclerosis onset before 21 years of age. Mothers and fathers are equally likely to transmit the disease, with no evidence of a Carter effect--where the parent who is less likely to be affected is more likely to transmit the disease (130). However, a high-risk mother (White) married to a low-risk husband (Aboriginal) is more likely to transmit multiple sclerosis to a daughter than a low-risk mother plus a high-risk father, suggesting a strong effect of maternal environment (258). Gender, age at onset, disease course, and severity are more similar than expected among patients in a family (150), but others believe phenotypes are not concordant (85). Children of patients (107), 10% of first-degree relatives, and unaffected twins often have abnormal MRIs (218), but their T cell responses to myelin basic protein are normal (200; 255). Other investigators find excessive responses to myelin antigens in normal family members. The large number of unaffected monozygotic twins (70%) is a strong argument for a significant environmental contribution. It is argued that some people can never develop multiple sclerosis (119).

No single Mendelian locus causes multiple sclerosis. However, a limited number of interacting genes might affect susceptibility (278). Linkage to DR2 (HLA-DRB1*1501, possibly with DQB1*0602) is strongest in Northern Europeans. Other HLA-DR subtypes are linked to multiple sclerosis in the Middle East, Turkey, and Sardinia. Western forms of multiple sclerosis are linked to DR2 (HLA-DRB1*1501) in Japan (159) and in Southern Han Chinese. DRB1*0901 is protective against the Western form of multiple sclerosis and is frequent in Orientals (30%) compared to Occidentals (1%) (351).

In Japanese and Chinese patients, with and without HLA DRB1*1501, multiple sclerosis often resembles Devic disease (eye and spinal cord involvement, infrequent CSF oligoclonal bands). Typical Western multiple sclerosis is much less likely. In Caucasians, Caribbeans, and Brazilians, DRB1*03 increases risk for Devic disease.

In Black Americans, African HLA ancestry with DRB1*1503 and DRB1*0405, correlates with disability. In Europeans, DR2 correlates with the presence of oligoclonal bands in the CSF but not with MRI lesions (301). DRB1*15 positive patients have greater gray and white matter damage and more T2 lesions than DRB1*15 negative patients. DR4 is linked to a primary progressive course (150). DR2 and DR4 links suggest two different HLA-linked mechanisms for central nervous system lesions. HLA-B12 has been linked to multiple sclerosis and, as fate would have it, to vitamin B12 deficiency and myelopathy. Resistance genes are HLA-Bw4, DRB5 (less progression and severity), DRB1*01, CDR1*14, B*4402, HLA-A*0201, and HLA-C*05.

Non-HLA genes detected with genome-wide association studies (GWAS) of thousands of patients show subtle links to the onset or course multiple sclerosis. These include T cell receptors, immunoglobulin allotypes, POU2AF1 (transcriptional coactivator that regulates immunoglobulin expression), complement factors (C6, C7, properdin), the IL-2 receptor beta chain, IL-7 receptor alpha chain, intercellular adhesion molecule-1 (K469E), tumor necrosis factor alleles, CD45 tyrosine phosphatase, CD24 (a heat stable antigen that enhances T cell persistence in the brain), synapsin III, and Tyk2 and 2,5-oligoadenylate synthase (OAS1) in the interferon response pathway, and possibly mitochondrial DNA. Other candidate genes code for myelin basic protein, transketolase, IL-10, chemokines, p53, estrogen and vitamin A receptors, Jagged1 (oligodendrocyte differentiation), and proteolytic enzymes such as calpain. Many of these correlations are highly significant, but biologically weak, with odds ratios of only 1.2.

Single nucleotide polymorphisms (SNPs) linked to multiple sclerosis are predominantly immune-related. They include the T-cell receptor-related SH2D2A, GM21* immunoglobulin haplotype, IL-1 and IL-2 receptor, IL-7 receptor alpha chain, CD6 (CD4 T cell proliferation), CD24 (costimulatory and antigen presentation), CD58 adhesion molecule, EOMES, LMP2 (proteosome MBP antigen processing), MLANA, (melanoma antigen recognized by T cells 1), THADA (thyroid adenoma-associated protein), IFN-gamma, IFN-gamma receptor (debated), STAT3, interferon regulatory factor-5 (IRF-5), MxA, OAS1, RAGE, TNFRSF1A (type I TNF receptor), chemokines (CCL3, CCL15, and others). Nonimmune SNPs include anti-Mullerian hormone, brain-derived neurotrophic factor (BDNF), P2X7 (purinergic receptor; small study), tissue plasminogen activator, GPC5, KIF1B (axonal transport of mitochondria and synaptic vesicles), mitochondrial complex I, free radical scavengers (para-oxonase I), anti-glycation (glyoxalase I), and CYP27B1 (vitamin D synthesis and degradation). Vitamin D response elements are present in HLA-DRB1, CD40, CXCR4, and CXCR5 genes, suggesting its importance.

The IL-7 receptor alpha link is weak. However, altered IL-7Ra function could be important in a subset of patients. IL-7 enhances immunity and affects thymic emigration, and the IL-7 receptor chain is upregulated by steroids, tumor necrosis factor, and type I interferons.

Some genes modify the course of multiple sclerosis but not susceptibility to the disease. These genes affect immune regulation and glial or neuronal vulnerability. Three percent of Europeans have a homozygous deletion of ciliary neurotrophic factor (CNTF), a growth factor for neurons (181). In this group, multiple sclerosis is more severe and onset is earlier (117). Mice lacking CNTF or leukemia inhibitory factor (LIF) have worse experimental allergic encephalomyelitis. ApoE4 may be more common in progressive forms of multiple sclerosis and augers cognitive impairment, a faster rate of disability progression, and more MRI destruction and deep gray matter atrophy, although some studies and a large meta-analysis find no link. APOE helps phagocytes clear toxic cholesterol ingested from damaged myelin. ApoB is linked to new T2 MRI lesions. Chemokine receptor-5 positive monocytes accumulate in multiple sclerosis lesions; CCR5+ T cells correlate with MRI lesions. A mutation of the receptor, CCR5-delta 32, (homozygous in 1% and heterozygous in 13% of Caucasians) protects against HIV infection by preventing its attachment to monocytes and protects against severe rheumatoid arthritis (198) and West Nile virus. This mutation is associated with the presence of multiple sclerosis (90) but slows progression (151). Other putative or unconfirmed genetic links to the course of multiple sclerosis include the IL-1beta receptor and IL-1 receptor antagonist, transforming growth factor-beta, immunoglobulin Fc receptors, CD24, CTLA-4, and phenylethanolamine N-methyl transferase (converts norepinephrine to epinephrine). TOB1 (transducer of ERBB2-1; inhibits interferon-beta transcription) is linked to exacerbations, and alphaB-crystallin is linked to progression. Multiple sclerosis is linked to ulcerative colitis, but not to lupus or autoimmune and neurodegenerative diseases. Overall, there is an excessive inflammatory response to multiple antigens, coupled with a decreased rate of virus infections and perhaps less cancer. Strong antipathogen responses without regulatory tempering may predispose to CNS damage. Some of these anti-pathogen immune genes arose in Neanderthals and, 5000 years ago, appeared in Yamnaya cattle herders (78).

Genetic risk scores have little meaning for an individual who is questioning her multiple sclerosis risk, however. Heritability is additive, from many common variants, each with weak effect.

Gene expression is highly dysregulated in untreated multiple sclerosis, in contrast to the subtle variation seen with genome-wide association studies. Expression of 8000 genes is abnormal in blood mononuclear cells of untreated patients versus healthy controls (91), replicated in a second cohort of patients (104). Another large group of genes has alternatively spliced RNA, adding to the complexity of the disease (266). These differentially expressed genes reflect a defect in immune regulation, leading to excessive inflammation, as well as dysregulation in the interferon system and neuroprotective pathways.

Response to putative target antigens. Antibody response is increased against certain viruses, particularly measles and Epstein-Barr virus. Antiviral antibodies are not specific for a single inciting agent, as they vary among plaques and among patients (205; 87).

Excessive antibody responses may be part of the immune dysregulation that characterizes multiple sclerosis, and a nonspecific rise in all titers would make it easier to detect specific antibodies. Nonspecific activation of B cells through immune dysregulation or exposure to viruses and CNS antigens are potential driving factors.

There is an increase of autoantibodies to 2,’3’ cyclic nucleotide 3’ phosphodiesterase (IgM), alphaB- and alphaA-crystallin (anti-inflammatory; astrocytes, oligodendroglia), anoctamin-2 (neurons, astrocytes), cardiolipin, chlamydia (debated), contactin-2/TAG-1 or contactin/TIP30 of the juxtaparanodal domain (rats), DNA, galactocerebroside, gangliosides (GM1, asilao-GM1, GD1a; plus GM3, which is highest in secondary progressive multiple sclerosis and primary progressive multiple sclerosis), glial fibrillary acidic protein (GFAP; in secondary progressive multiple sclerosis, strong correlation with clinical deficits), GlialCAM (astrocytes), glycans, glyceraldehyde-3-phosphate dehydrogenase (GAPDH, linked to fatigue), glycopeptides, heat shock proteins 60 and 90, myelin proteins (CNP, MAG, MBP, MOG, OSP, phosphatidylcholine, and PLP), neurofilament light chains (axons), neutrophil cytoplasmic antigen, NG-2 (AN-2), Nogo (debated), nuclear antigens, proteasomes, RASGBP brain, NK, B, and CD8 cells, transaldolase, thyroid microsomal antigens, smooth muscle, and thyroglobulin (271). Autoantibodies are most detectable during exacerbations and in progressive forms of multiple sclerosis (303). Some may contribute to brain damage and progression or may reflect immune responses to newly visible brain antigens. IFN-beta does not induce autoantibodies, but interferon therapy on a background of autoantibodies is more likely to lead to neutralizing antibodies to the drug.

Excessive T cell reactions to brain antigens approach the threshold of statistical significance. This might be expected with chronic inflammatory damage of the central nervous system and does not prove causation. Myelin basic protein-reactive T cells are more common than in controls, especially when high avidity cells are detected with low, physiologically relevant levels of MBP (30). Importantly, more frequent MBP-reactive cells are equivalent between patients and their normal family members (106), maybe reflecting familial HLA-regulated responses.

Cytokine production in both innate and adaptive immunity is hereditary and predicts the type of multiple sclerosis. Th1 responses are strongly linked in families, with 0.8 to 0.9 hereditability. In healthy family members of patients, lipopolysaccharide-stimulated IL-10 is reduced by 12%, and TNF-alpha is increased by 10% compared to multiple sclerosis-free families. Low IL-10 plus high TNF-alpha in a family predicts a 4-fold increased risk of developing multiple sclerosis and an 8-fold increase of relapsing-remitting over primary progressive multiple sclerosis (71).

Environmental influences. The “exposome” strongly affects the risk of developing multiple sclerosis (132). Migrants to a low incidence area have a smaller risk than if they had remained in situ (Ebers and 278). Asians and Latinos maintain their low risk after migration (76; Ebers and 278). People who migrate from a low incidence area to a high incidence area before the age of 15 years have a high risk, but after the age of 15, migration does not affect the risk of developing multiple sclerosis.

The ratio of “Asian” (prominent optic nerve and spinal cord demyelination) to “Western” clinical phenotypes has changed in Japan from 2:1 in patients who were born in the 1920s to 1:4 in patients born in the 1970s (160). This suggests the form of multiple sclerosis is greatly modified by environmental alterations, likely diet, hygiene, antibiotic use, and exposure to bacteria and viruses. This evolution of the clinical character of multiple sclerosis could alter responses to multiple sclerosis therapies.

Canine distemper virus, related to measles, or other viruses carried by small house pets were once implicated in the development of multiple sclerosis, but the association was likely from recall bias during epidemiological surveys. Many patients had not been exposed. Nonetheless, anti-measles antibodies are high in multiple sclerosis CSF and might be linked to measles-induced profound acute immunosuppression and long-term loss of 50% of memory T and B cells (212). Epstein-Barr virus titers are also elevated but can sometimes reflect the excess antibody responses in the disease (Section 2). Army recruits who become positive, however, have a 32-fold increased risk of developing multiple sclerosis (37). In the Faroe Islands, four epidemics of multiple sclerosis appeared after British troops occupied the islands in 1940 through 1944. Multiple sclerosis onset was attributed to a virus carried by the British. The putative virus required prolonged exposure (2 years) in people 11 to 45 years of age and was theorized to cause multiple sclerosis 5 to 8 years after exposure (169). It is also possible that contact with a multiple sclerosis agent at an early age (0 to 3 years old) is protective, as Faroese born between 1941 and 1945 do not have multiple sclerosis (58).

Multiple sclerosis is not transmitted vertically (breast milk), through transfusions, or conjugally. Doctors, nurses, and spouses of patients do not have an increased incidence of multiple sclerosis. Lack of transmission argues against known viral or retroviral infections in adults.

Environment changes the course of multiple sclerosis. One third of upper respiratory infections will trigger an exacerbation (296; 235; 60) and increase new MRI lesions during the “at risk” period, especially in early multiple sclerosis (295). Picornaviruses, and perhaps all rhinoviruses, may be the most potent triggers. Nonetheless, virus infections decrease by 20% to 50% in multiple sclerosis (296), especially when the disease becomes rapidly progressive (295). Bacterial infections increase exacerbations by 3-fold (260; 60). Excessive inflammation and altered interferon regulation may protect against infections (93).

Interferon therapy does not reduce virus infection rates, but it prevents virus infections from triggering exacerbations (234). There seems to be no effect of interferon-neutralizing antibodies on infections.

Smokers induce multiple sclerosis in themselves and their children and also enflame ongoing multiple sclerosis. The relative risk from smoking is 1.5, but combined with HLA-DRB*15+ and HLA-A*02-, this rises to 14-fold more risk (127). Smoking and obesity synergize, with adverse effects on disease worsening and cognition. Forty one percent of new cases in Sweden with the latter profile are in smokers. Smokers have a 60% increase in exacerbations, double the rate of progression, more conversion to progression, more new MRI lesions, and double the rate of brain atrophy. During the BENEFIT study of IFN-beta-1b after first demyelination, there was no effect of smoking on occurrence of the next attacks, progression, or MRI lesions (220). IFN-beta therapy prevents disease and MRI activity and enhances brain repair, perhaps obscuring the detriment of smoking in this study. Oral tobacco containing nicotine reduces the risk of multiple sclerosis (127). This suggests that lung irritation by smoking and vaping, environmental particulate matter, and volatile organics, perhaps through the aryl hydrocarbon receptor (above), activates pulmonary and systemic immunity. Smoking also increases anti-Epstein-Barr virus antibody titers and the formation of neutralizing antibodies to natalizumab and interferon-beta therapies.

Physical activity and body morphology affect the incidence and severity of multiple sclerosis. Obesity in teenagers doubles the chance they will develop multiple sclerosis (128). Obesity paired with HLA-DRB*15+ and “HLA-A*02- increases risk of developing multiple sclerosis to 15-fold. Obesity also lowers serum vitamin D levels. High-fat, high-salt diets and multiple proinflammatory products of adipose tissue affect immune regulation, especially during the critical teen years. Adipocytes and high-fat diets inhibit B cell lymphopoiesis and function and increase infections and activate microglia. High cholesterol increases lipid raft mobility in CD8 cell membranes and thereby enhances immune activation. In contrast, high-density lipoprotein (HDL) attenuates Th1 and Th17 function and cytokine production, potentially beneficial in multiple sclerosis. High serum omega-3 polyunsaturated fatty acids (PUFA) reduce MRI T2 lesions. Four cups of coffee per day may prevent development of multiple sclerosis.

Triggers of exacerbation include postpartum period and also cranial irradiation (332). Exposure to interferon-gamma, altered peptide ligands, or anti-TNF antibodies causes exacerbations. A relationship with stress and head trauma is unlikely yet strongly debated in court. Menopause accelerates progression and disability; perimenopausal estriol supplements temporarily reverse this. Shift-work and lack of sleep, especially in the teen years, increases risk of developing multiple sclerosis by 50%.

Environmental antigens and age shape immune responses. A dirty environment (ie, viral and bacterial exposure) allows development of experimental allergic encephalomyelitis in transgenic mice with V-beta-8.2, V-alpha-2.3, and myelin basic protein-specific T cell antigen receptor genes. However, no lesions developed in identical transgenic mice raised in a clean, specific pathogen-free facility (121). It is very difficult to induce experimental allergic encephalomyelitis in wild mice, perhaps because of broad microbial exposure and lack of inbreeding. In humans, all environments contain pathogens. Type and timing of exposure could affect immunity and tolerance. Parasites and a rich microbiome balance the evolutionary selection of interleukin polymorphisms that are effective against viruses and bacteria. Exposure to infant siblings during the first 6 years of life decreases the incidence of multiple sclerosis by up to 8-fold (244). Regions with a high incidence of multiple sclerosis have a low incidence of hepatitis B and schistosomes. Patients with multiple sclerosis have more education and higher socioeconomic status than average, perhaps reducing pathogen exposure. Sanitation may be better, and childhood infections occur later in these patients than in the general population (05). "Clean" environments and late-in-childhood infections seem predispose or trigger an autoimmune or bystander reaction in multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease--the “hygiene hypothesis.”

Dental caries correlate with higher incidence of multiple sclerosis. Periodontal disease bacteria increase the severity of experimental allergic encephalomyelitis and drive Th17 responses and arthritis. Oral bacteria also activate latent HIV-1; effects on endogenous retroviruses have not been studied.

Intestinal microflora create an enormous and diverse ecosystem. Most of their bacterial RNA sequences are from novel, often uncultivated microorganisms. Gut bacteria activate immune cells, guiding immune tolerance to food antigens and self-antigens through production of immunosuppressive short-chain fatty acids. Immune-privileged sites, such as the brain, however, could be insulated from this mechanism. Complex gut flora strengthen the blood-brain barrier. Importantly, dietary antigens and probiotics directly shape the gut immune system and can induce peripheral regulatory T cells.

Skin, mouth, airways, and breast milk contain unique flora, as does the vagina, where the microbiota vary with race and change after menopause. Maternal diet during gestation and lactation influence immunity in offspring, a “lard legacy.” Caesarean section prevents contact with vaginal bacteria during delivery, increasing the risk of immune-mediated diseases. Compared to bottled milk, breast milk induces robust populations of memory and Th17 T cells. Maternal cells transfer immune knowledge to the child, “maternal educational immunity.” Bacteroides fragilis and Lactobacillus spp. in the gut microbiome help maintain blood-brain barrier permeability, increase regulatory B and T cells, reduce Th17 cells, and also control fat storage and obesity, change behavior, and regulate some virus infections.

A Western diet of high sugar, animal fat, and protein is associated with specific bacterial enterotypes. A high-sugar, high-fat diet disrupts bacteria that control immunosuppressive lipid absorption in the intestine. Free fatty acids and lipopolysaccharide stimulate TLR4 and amplify inflammatory bowel disease and possibly other autoimmune conditions. Other metabolites can stimulate the aryl hydrocarbon receptor and maintain intestinal immunity. In contrast, dietary fiber induces beneficial bacterial families that break down fiber to produce immunosuppressive acetate and propionate. Some microbiota (eg, Bacteroides fragilis) induce IL-10-secreting regulatory T cells; others induce Th17 or Th1 proinflammatory cells (141). The intestine in multiple sclerosis contains high numbers of Clostridium perfringens which produce epsilon toxin (190). This toxin binds to an endothelial cell protein, allowing breach of the blood-brain barrier and also targets immune cells (262).

Antibiotics have prolonged effects on some gut microbiota taxa. Antibiotic treatment of H pylori prevents peptic ulcers and gastric cancer but increases risk of gastro-esophageal reflux disease (GERD) and esophageal cancer. Women with multiple sclerosis have lower rates of H pylori infections compared to controls, and H pylori-negative women have less progression than those who are positive. Antibiotics reduce complexity of the microbiome and shift immunity from a mix of Th17 and T-regulatory cells to one of Th17 predominance in mice. A more extreme effect appears in the intensive care unit; combinations of stress, critical illness, antibiotics, proton pump inhibitors, H2 blockers, opiates, and ischemia will increase virulence of gut flora and allow emergence of pathogenic, ultra-low diversity bacterial communities (06). They induce IL-17 and tumor necrosis factor, cytokines that enhance resistance to some intestinal pathogens but that could also trigger autoimmunity. Antibiotic use actually correlates with increased risk of multiple sclerosis, from 1.08 to 1.83, depending on the type of antibiotic (227). The risk could be related to pretreatment infections or to a change in microbiota. Multiple sclerosis therapies change the microbiota. Interferon-beta increases anti-inflammatory acetic, propionic, and butyric acids.

Some bacteria, “probiotics,” and parasitic infestation with helminths induce Th2 responses and reduce the severity of experimental colitis and human ulcerative colitis and Crohn disease. Lactobacillus (in yogurt) increases IFN-alpha and IFN-beta levels. Other probiotics increase Th1 or Treg responses (54). Infestation with parasites may prevent multiple sclerosis from developing (103). In patients with relapsing/remitting disease, parasites induce eosinophilia--but also more regulatory macrophages, T and B cells, plus secretion of anti-inflammatory IL-4, IL-10, and transforming growth factor-beta, but less pro-inflammatory IFN-gamma and IL-12. Parasites also reduce new MRI lesions, clinical progression, and attack frequency 20-fold (59). Antiparasitic treatment reverses this and causes clinical and MRI multiple sclerosis activity. A trial of ova from Trichuris suis, the pork whipworm (not the human form, Trichuris trichiura), had no benefit, however (103). Although oral tolerance with myelin basic protein does not affect the course of multiple sclerosis, the richer multi-antigenic repertoire of parasites and probiotics might have benefit.

Vitamin D affects the onset and the course of multiple sclerosis (299). Correlations with serum vitamin D levels could be incomplete because low sun exposure and vitamin D intake are independent predictors of first demyelinating events (185). Sunlight and ultraviolet radiation are strong inducers of IL-10, beta-defensins, and Th2 and Treg responses in skin. Illustrating this immune suppression, sunburn blocks immune responses to vaccination and various antigens. It is unknown whether sun-induced fluctuations in IL-10 and other cytokines affect the course of multiple sclerosis.

Vitamin D is immunosuppressive. It induces cAMP, IL-4, and transforming growth factor-beta, and it inhibits production of IL-2, IL-12, IFN-gamma, and TNF-alpha. It slows proliferation of CD4 T cells, B cells, and plasma cells and inhibits function of Th1 and type I dendritic cells. Vitamin D causes a shift to Th2 cytokine production and also enhances interferon-beta signaling, suggesting a synergistic therapeutic effect (95). CD8 cells express 2- to 3-fold more vitamin D receptors than CD4 cells, and receptors increase on activated T cells. Vitamin D inhibits onset (more in females) and relapses of experimental allergic encephalomyelitis via an IL-10 pathway. It also induces regulatory T cells (116). Regulatory T cells migrate from the mother into fetal lymph nodes (214), affecting the fetus (below).

Provitamin 7-dehydrocholesterol is synthesized in the skin. Ultraviolet sunlight converts it to vitamin D3 (cholecalciferol), which is further modified in liver and then in renal mitochondria to active calcitriol (1,25(OH)2D3). Foods high in vitamin D include fatty seafood, liver, egg yolks (D3), and chanterelle and portabella mushrooms, especially if grown with UV light (ergocalciferol, vitamin D2). Vitamin D intake is inadequate in many seemingly healthy people.

Children of mothers with serum vitamin D levels in the lowest quintile are twice as likely to develop multiple sclerosis (219). Mothers with high milk or vitamin D intake are less likely to have children who develop multiple sclerosis and children with poor cognitive function. Serum vitamin D levels fluctuate with the seasons, possibly linked to the May/November birth month ratio of 1.43 for development of multiple sclerosis (279). More people with multiple sclerosis are born in the springtime than in the fall, suggesting low vitamin D affects the fetus during the winter. Total births also increase in spring, paralleling more frequent multiple sclerosis. Even after correcting for the springtime increase in total births, multiple sclerosis increases in April births (1.24) but decreases in November births (0.84) (275). Others disagree (97). Suggesting a relationship between low vitamin D and less autoimmunity, low serum vitamin D levels in May births are associated with more thymic output of new T cells (RTE; Trecs) (79), which are preferential precursors of peripheral CD4 naive and CD4 regulatory T cells. High serum vitamin D levels correlate with longer telomere length in women, suggesting an effect on longevity.

Seasonal variation in multiple sclerosis activity differs in various locales (120), perhaps related to vitamin D intake, sunlight, or exposure to viruses and parasites. MRI activity peaks in late springtime (13), correlating with low serum vitamin D levels. Relapses are most likely 1 month after the serum vitamin D seasonal trough, and the gap between exacerbations shrinks with distance from the equator (304). Vitamin D enhances interferon-beta signaling and shifts cytokines to Th2 immunity (95). Supplementation enhances the therapeutic effect of interferon-beta (below).

Tasmanian children exposed to large amounts of sunlight, especially in winter, are one third as likely to develop multiple sclerosis later in life (326). Consumption of fatty fish, outdoor work, and rural life prevent development of multiple sclerosis and reduce mortality from multiple sclerosis. Nurses taking vitamin D supplements (greater than or equal to 400 IU daily) are 40% less likely to develop multiple sclerosis (221; 244), though their lifestyle could differ from those without vitamin D supplements. Similar correlations are seen in Norway (148). Subjects with darker buttock skin (a measure of genetic background, presumably not exposed to sunlight) were less likely to develop multiple sclerosis. Whites have higher vitamin D levels than Blacks; levels in Whites correlate with resistance to development of multiple sclerosis. In France, the regional multiple sclerosis prevalence matches the amount of cloud cover. Women shrouded for religious reasons develop osteoporosis, especially in Northern European countries; this could increase their risk of multiple sclerosis. In contrast to these data, multiple sclerosis appears to have been much less common during the industrial revolution when the sun was obscured by industrial smoke. Different pathogen exposure and early mortality may explain this discrepancy.

Vitamin D increases intestinal calcium uptake and promotes bone mineralization. Multiple sclerosis patients can have low vitamin D levels and demineralized bone due to a combination of fear of the sun’s heat, treatment of pain with antiepileptic drugs, immobility, disrupted sympathetic innervation of bone (depression and sympathetic hyperactivity is linked to osteoporosis), and possibly to subnormal interferon responses in untreated multiple sclerosis (because interferon therapy enhances bone formation) (93). Vitamin D3 induces interferon-beta production by osteoclast progenitors, and the interferon inhibits osteoclast formation (282). Even at the onset of multiple sclerosis, bone mineral density and vitamin D levels are low. Surprisingly, vitamin D metabolic pathway genes do not correlate with multiple sclerosis risk.

Melatonin has complex effects. This indoleamine antioxidant prevents carcinogenesis but is anti-apoptotic in noncancer cells. Melatonin induces neuroprotective Nrf. It also stimulates Th1 pathways (inhibits cAMP and induces IL-1, 2, 6, 12, and 18). Serum melatonin levels are inversely correlated with multiple sclerosis activity, but sleep is disturbed in multiple sclerosis, so correlations may not indicate causation. Melatonin is elevated by IFN-beta therapy.

Other environmental factors that may increase multiple sclerosis disease activity include in vitro fertilization (LHRH agonists), exposure to wool or sheep, and consumption of smoked sausage or fresh cow milk (the milk protein, butyrophilin, shares antigens with myelin oligodendrocyte glycoprotein). A high socioeconomic status confounds some of these factors (28). Regular smoking doubles the risk of having multiple sclerosis; men are more susceptible than women, and adolescence may be a critical period of susceptibility (below). Salt consumption has been proposed as fomenting Th17 cell responses, amplifying experimental allergic encephalomyelitis, exaggerating the pro-inflammatory effects of aldosterone, and inducing salt-sensing serum glucocorticoid kinase (SGK1) (325). However, there is minimal epidemiologic evidence for salt induction of autoimmune diseases or multiple sclerosis.

Obesity in adolescents and young adults doubles the risk of developing multiple sclerosis and later clinical and MRI activity. Leptin and adiponectin, made by adipocytes, are proinflammatory. Leptin (Greek “thin,” small) promotes weight loss, hair growth, wound healing, atherosclerosis, breast cancer, and autoimmunity and induces inflammatory Th17 cells. Fasting mice have lower leptin levels, inducing Treg expansion and less immune infiltration into the CNS. Serum leptin is increased in multiple sclerosis (203). Adiponectin also activates dendritic cells to induce Th1 and Th17 cells. IL-17 feedback inhibits expression of these adipocyte genes and causes weight loss.

A diet low in saturated fats (the Swank diet) or rich in antioxidants (Wahls diet) or treatment with evening primrose oil (rich in linoleic and gamma-linolenic acids) reduce fatigue and improve quality of life (334) (no placebo group) and may modestly lower the rate of exacerbations (84; 333), but this has been disputed (315). Diet and supplements may add to the benefit of multiple sclerosis therapies.

Alcohol consumption has a strong dose-dependent inverse relationship with the onset of multiple sclerosis (128) and also in multiple autoimmune diseases. It also attenuates the negative effects of cigarette smoking.

Low association with autoimmune diseases. Few autoimmune diseases are associated with multiple sclerosis (264; 347). There are scattered reports of multiple sclerosis coexisting with ulcerative colitis or Crohn disease and possibly with myasthenia gravis, type I diabetes, narcolepsy (also HLA-DR2-linked), and thyroid disease. Other associations are lacking or actually decreased in multiple sclerosis. This suggests that the etiology of multiple sclerosis differs from other autoimmune diseases. Therapy with alemtuzumab (anti-CD52, Campath-1H) induces antithyroid antibodies, presumably by altering immune regulation and perhaps neuronal function and synapse formation. Importantly, the demyelinating mimic of multiple sclerosis, Devic disease/neuromyelitis optica, is highly associated with autoimmune diseases (10-fold increase). Epidemiological mixing of multiple sclerosis with this variant leads to spurious associations of “multiple sclerosis” with autoimmune diseases such as lupus and Sjögren syndrome.

Some diseases are infrequent in multiple sclerosis. Asthma and allergies are half as common as in the general population. Cancer is reduced by two thirds or three fourths in multiple sclerosis compared to controls (280; 162; 15). During trials of subcutaneous IFN-beta-1a, the reported to expected ratio of cancer was reduced by over 10-fold, with 50% more cases in the placebo groups than in the interferon groups (283; 233). Multiple sclerosis patients have low uric acid levels and rarely develop gout. Uric acid ameliorates experimental allergic encephalomyelitis but not multiple sclerosis.

Interferons control virus infections. In multiple sclerosis, however, there is altered activation of STAT1 transcription factor, Iow serum type I interferon levels, and subnormal immune cell responses to interferon; interferon therapy is beneficial (143; 94). Likely related, interferon levels affect some disease correlations. There is a strong negative association with Down syndrome, possibly because chromosome 21 codes for type I interferon receptors, increasing the set point of responses to interferon (342). Perhaps related, lupus is rare in multiple sclerosis. Lupus immune cells produce excessive interferon and are hyperresponsive to it; interferon therapy causes lupus exacerbations.

Media

References

01: Absinta M, Nair G, Monaco MC, et al. The "central vein sign" in inflammatory demyelination: the role of fibrillar collagen type I. Ann Neurol 2019;85(6):934-42. PMID 30847935
02: Ahn J, Feng X, Patel N, Dhawan N, Reder AT. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: Implications for control of apoptosis. Front Biosci 2004;9:1547-55. PMID 14977566
03: Albert M, Antel J, Bruck W, Stadelmann C. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol 2007;17:129-38.** PMID 17388943
04: Alter M, Kahana E, Zilber N, Miller A. Multiple sclerosis frequency in Israel's diverse populations. Neurology 2006;66:1061-6. PMID 16606919
05: Alter M, Zhang ZX, Davanipour Z, et al. Multiple sclerosis and childhood infections. Neurology 1986;36:1386-9. PMID 3762950
06: Alverdy J, Zaborina O, Wu L. The impact of stress and nutrition on bacterial-host interactions at the intestinal epithelial surface. Curr Opin Clin Nutr Metab Care 2005;8(2):205-9.** PMID 15716801
07: Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992;31:333-6.** PMID 1637140
08: Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, Nataf S. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 2010;68(4):465-76.** PMID 20687208
09: Ankeny DP, Lucin KM, Sanders VM, McGaughy VM, Popovich PG. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J Neurochem 2006;99(4):1073-87. PMID 17081140
10: Antel JP, Arnason BG, Medof ME. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 1979;5:338-42.** PMID 312620
11: Antel JP, Bania MB, Reder AT, Cashman N. Activated suppressor cell dysfunction in chronic progressive multiple sclerosis. J Immunol 1986;137:137-41. PMID 2940299
12: Astrom KE, Webster HD, Arnason BG. The initial lesion in experimental allergic neuritis: a phase and electron microscopic study. J Exp Med 1968;128(3):469-95.** PMID 4875326
13: Auer DP, Schumann EM, Kumpfel T, Gossl C, Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;47:276-7. PMID 10665507
14: Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000;192:393-404. PMID 10934227
15: Bahmanyar S, Montgomery S, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009;72:1170-7.** PMID 19332695
16: Bakshi R, Minagar A, Jaisani Z, Wolinksy JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx 2005;2(2):277-303. PMID 15897951
17: Balabanov R, Strand K, Goswami R, et al. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J Neurosci 2007;27:2013-24. PMID 17314297
18: Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999;96:6873-8. PMID 10359806
19: Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 1997;94:599-603.** PMID 9012830
20: Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123:2321-37. PMID 11050032
21: Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999;5:283-6. PMID 10467389
22: Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60(8):1073-81.** PMID 12925362
23: Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009;65(1):32-46. PMID 19194879
24: Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-68.** PMID 15048884
25: Baslow MH. Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system: An analytical review. Neurochem Int 2002;40:295-300. PMID 11792458
26: Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations. Acta Neurol Scand 1988;78:318-23.** PMID 3146861
27: Bennett JL, Haubold K, Ritchie AM, et al. CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. J Neuroimmunol 2008;199:126-32.** PMID 18547652
28: Ben-Shlomo Y. Dietary fat in the epidemiology of multiple sclerosis: has the situation been adequately assessed. Neuroepidemiology 1992;11:214-25.** PMID 1291885
29: Bergers E, Bot JC, De Groot CJ, et al. Axonal damage in the spinal cord of multiple sclerosis patients occurs largely independent of T2 MRI lesions. Neurology 2002;59:1766-71. PMID 12473766
30: Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004;172:3893-4. PMID 15004197
31: Biernacki K, Antel JP, Blain M, Narayanan S, Arnold DL, Prat. A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005;62:563-8. PMID 15824253
32: Birk K, Ford C, Smeltzer S, Ryan D, Miller R, Rudick RA. The clinical course of multiple sclerosis during pregnancy and the puerperium. Arch Neurol 1990;47:738-42.** PMID 1972617
33: Birnbaum G, Kotilinek L, Schlievert P, et al. Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): immunization with a peptide of the myelin protein 2’, 3’ cyclic nucleotide 3’ phosphodiesterase that is cross-reactive with a heat shock protein alters the course of EAE. J Neurosci Res 1996;44:381-96. PMID 8739158
34: Bischof A, Papinutto N, Keshavan A, et al. Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. Ann Neurol 2022;91(2):268-81. PMID 34878197
35: Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000;123:1174-83.** PMID 10825356
36: Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-8.** PMID 11371748
37: Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022;375(6578):296-301. PMID 35025605
38: Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008;8(4):793-802. PMID 18261176
39: Booss J, Esiri MM, Tourtellotte WW, Mason DY. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 1983;62:219-32. PMID 6607973
40: Boullerne AI, Rodriguez JJ, Touil T, et al. Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neurosci 2002;22:123-32. PMID 11756495
41: Brass SD, Narayanan S, Antel JP, Lapierre Y, Collins L, Arnold DL. Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci 2004;31:225-8. PMID 15198448
42: Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008;63:16-25. PMID 18232012
43: Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006;12(2):143-8. PMID 16629417
44: Brier MR, Judge B, Ying C, et al. Increased white matter aerobic glycolysis in multiple sclerosis. Ann Neurol 2025;97(4):766-78.** PMID 39714123
45: Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlations of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-93.** PMID 9392578
46: Buljevac D, Hop W, Reedeker W, et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. Br Med J 2003;327:646-51. PMID 14500435
47: Byskosh PV, Reder AT. Interferon-beta effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler 1996;1:262-9. PMID 9345428
48: Calabrese M, Preziosa P, Scalfari A, et al. Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol 2024;96(1):1-20.** PMID 38568026
49: Calabrese M, Rocca MA, Atzori M, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009;72:1330-6. PMID 19365054
50: Calabrese M, Romualdi C, Poretto V, et al. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann Neurol 2013;74(1):76-83. PMID 23494723
51: Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-35. PMID 7536402
52: Chang A, Staugaitis SM, Dutta R, et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol 2012;72(6):918-26. PMID 23076662
53: Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002;346:165-73.** PMID 11796850
54: Chattha KS, Vlasova AN, Kandasamy S, Rajashekara G, Saif LJ. Divergent immunomodulating effects of probiotics on T cell responses to oral attenuated human rotavirus vaccine and virulent human rotavirus infection in a neonatal gnotobiotic piglet disease model. J Immunol 2013;191(5):2446-56. PMID 23918983
55: Ciccarelli O, Altmann DR, McLean MA, et al. Spinal cord repair in multiple sclerosis: does mitochondrial metabolism play a role. Neurology 2010;74(9):721-7. PMID 20107138
56: Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650-3. PMID 12402265
57: Compston DA, Vakarelis BN, Paul E, McDonald WI, Batchelor JR, Mims CA. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 1986;109:325-44. PMID 3456817
58: Cooke RG. Multiple sclerosis in the Faroe Islands and the possible protective effect of early childhood exposure to the “multiple sclerosis agent.” Acta Neurol Scand 1990;82:230-3. PMID 2270752
59: Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007;61:97-108.** PMID 17230481
60: Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67(4):652-9. PMID 16870812
61: Correale J, Gilmore W, Lopez J, Li SQ, McMillan M, Weiner LP. Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis. Nat Med 1996;2:1354-60.** PMID 8946835
62: Correale J, Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J Neuroimmunol 2008;195:121-34.** PMID 18234356
63: Couturier N, Zappulla JP, Lauwers-Cances V, et al. Mast cell transcripts are increased within and outside multiple sclerosis lesions. J Neuroimmunol 2008;195:176-85. PMID 18374990
64: Craner MJ, Damarjian TG, Liu S, et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and multiple sclerosis. Glia 2005;49:220-9. PMID 15390090
65: Cross AH, Trotter JL, Lyons JA. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001;112:1-14. PMID 11108928
66: Crucian B, Dunne P, Friedman H, Ragsdale R, Pross S, Widen R. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol 1995;2:249-52. PMID 7697540
67: Cui QL, Khan D, Rone M, et al. Sublethal oligodendrocyte injury: a reversible condition in multiple sclerosis? Ann Neurol 2017;81(6):811-24. PMID 28470695
68: Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72(8):705-11. PMID 19073945
69: De Jager PL, Baecher-Allan C, Maier LM, et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci USA 2009;106(13):5264-9. PMID 19237575
70: de Jong BA, Huizinga TW, Bollen EL, et al. Production of IL-1alpha and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002;126:172-9. PMID 12020968
71: de Jong BA, Schrijver HM, Huizinga TW, et al. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann Neurol 2000;48:641-6. PMID 11026448
72: De Keyser J, Wilczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 1999;53:1628-33. PMID 10563603
73: Dean G. How many people in the world have multiple sclerosis. Neuroepidemiology 1994;13:1-7.** PMID 8190200
74: DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006;129:1507-16. PMID 16597651
75: Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15(9):545-58. PMID 26250739
76: Detels R, Visscher BR, Malmgren RM, Coulson AH, Lucia MV, Dudley JP. Evidence for lower susceptibility to multiple sclerosis in Japanese-Americans. Am J Epidemiol 1977;105:303-10. PMID 848479
77: Dettke M, Scheidt P, Prange H, Kirchner H. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J Clin Immunol 1997;17:293-9.** PMID 9258768
78: Diamond J. Guns, germs, and steel: the fates of human societies. New York: W.W. Norton & Company, 1997.**
79: Disanto G, Watson CT, Meier UC, Ebers GC, Giovannoni G, Ramagopalan SV. Month of birth and thymic output. JAMA Neurol 2013;70(4):527-8. PMID 23568650
80: Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092-9. PMID 17475834
81: Duran I, Martinez-Caceres EM, Rio J, Barbera N, Marzo ME, Montalban X. Immunological profile of patients with primary progressive multiple sclerosis: expression of adhesion molecules. Brain 1999;122:2297-307. PMID 10581223
82: Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499-509.** PMID 19475668
83: Durfee J, Weinstock-Guttman B, Stosic M, et al. Cigarette smoking accelerates the evolution of brain atrophy and influences the severity of blood-brain-barrier disruption in multiple sclerosis. Neurology 2008;70:A465, P08.147.
84: Dworkin RH, Bates D, Millar JH, Paty DW. A re-analysis of three double-blind trials. Neurology 1984;34:1441-5.** PMID 6387534
85: Ebers GC, Koopman WJ, Hader W, et al. The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis. Brain 2000;123 Pt 3:641-9.** PMID 10686184
86: Ebers GC, Sadovnick AD. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology 1993;12:1-5. PMID 8327018
87: Enose-Akahata Y, Wang L, Almsned F, et al. The repertoire of CSF antiviral antibodies in patients with neuroinflammatory diseases. Sci Adv 2023;9(1):eabq6978. PMID 36598996
88: Fadda G, Brown RA, Magliozzi R, et al. A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis. Ann Neurol 2019;85(3):340-51. PMID 30719730
89: Fassbender K, Schmidt R, Mossner R, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 1998;55:66-72. PMID 9443712
90: Favorova OO, Andreewski TV, Boiko AN, et al. The chemokine receptor CCR5 deletion mutation is associated with multiple sclerosis in HLA-DR4-positive Russians. Neurology 2002;59:1652-5. PMID 12451219
91: Feng X, Bao RY, Li L, Deisenhammer F, Arnason BG, Reder AT. Interferon-β corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection. Lancet EBioMedicine 2019a:49:269-83. PMID 31648992
92: Feng X, Han D, Kilaru BK, Franek BS, Niewold TB, Reder AT. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol 2012b:1-7. PMID 22801747
93: Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Decreased expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002a;129:105-15.** PMID 12161037
94: Feng X, Reder NP, Yanamandala M, et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci 2012a;313(1-2):48-53.** PMID 22036215
95: Feng X, Wang Z, Howlett-Prieto Q, Einhorn N, Causevic S, Reder AT. Vitamin D enhances responses to interferon-beta in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2019b;6(6):1-13. PMID 31582399
96: Feng X, Yau D, Holbrook C, Reder AT. Type I interferons inhibit IL-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res 2002b;22(3):311-9. PMID 12034038
97: Fiddes B, Wason J, Kemppinen A, Ban M, Compston A, Sawcer S. Confounding underlies the apparent month of birth effect in multiple sclerosis. Ann Neurol 2013;73(6):714-20. PMID 23744589
98: Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-7.** PMID 12538409
99: Filippi M, Preziosa P, Langdon D, et al. Identifying progression in multiple sclerosis: new perspectives. Ann Neurol 2020;88(3):438-52.** PMID 32506714
100: Filippi M, Rocca MA, Camesasca F, et al. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011;76(14):1222-8.** PMID 21464426
101: Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64(3):255-65.** PMID 18661561
102: Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17. PMID 18234696
103: Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology 2006;67(11):2085-6.** PMID 17159130
104: Fogel A, Olcer M, Goel A, Feng X, Reder AT. Novel biomarkers and interferon signature in secondary progressive multiple sclerosis. J Neuroimmunol 2024;389:578328. PMID 38471284
105: Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008;9(11):839-55. PMID 18931697
106: Fredrikson S, Soderstrom M, Hillert J, Sun JB, Kall TB, Link H. Multiple sclerosis: occurrence of myelin basic protein peptide-reactive T cells in healthy family members. Acta Neurol Scand 1994;89:184-9.** PMID 7518178
107: Fulton JC, Grossman RI, Mannon LJ, Udupa J, Kolson DL. Familial multiple sclerosis: volumetric assessment in clinically symptomatic and asymptomatic individuals. Mult Scler 1999;5:74-7. PMID 10335514
108: Furlan R, Brambilla E, Ruffini F, et al. Intrathecal delivery of IFN-gamma protects C57 BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001;167:1821-9.** PMID 11466408
109: Gaitan MI, de Alwis MP, Sati P, Nair G, Reich DS. Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins. Neurology 2013;80(2):145-51. PMID 23255828
110: Gaitan MI, Shea CD, Evangelou IE, et al. Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011;70(1):22-9. PMID 21710622
111: Gay F. Bacterial toxins and multiple sclerosis. J Neurol Sci 2007;262:105-12. PMID 17707408
112: Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997;120(Pt 8):1461-83. PMID 9278635
113: Genc K, Altungoz O, Pekcetin C. The effect of IFN-beta on IFN gamma-induced B7 costimulation molecule expression on microglial cells in vitro. Mult Scler 1997a;3:312.
114: Genc K, Dona DL, Reder AT. Increased CD80+ B cells in active multiple sclerosis, and reversal by interferon beta-1b therapy. J Clin Invest 1997b;99:2664-71. PMID 9169496
115: Geurts JJ, Bo L, Roosendaal SD, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 2007;66:819-27.** PMID 17805012
116: Ghoreishi M, Bach P, Obst J, et al. Expansion of antigen-specific regulatory T cells with the topical vitamin D analog calcipotriol. J Immunol 2009;182:6071-8. PMID 19414758
117: Giess R, Maurer M, Linker R, et al. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 2002;59:407-9.** PMID 11890844
118: Golan D, Somer E, Dishon S, Cuzin-Disegni L, Miller A. Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann Neurol 2008;64:143-8. PMID 18570326
119: Goodin DS, Khankhanian P, Gourraud PA, Vince N. Multiple sclerosis: exploring the limits and implications of genetic and environmental susceptibility. PLoS One 2023;18(6):e0285599. PMID 37379505
120: Goodkin DE, Hertsgaard D. Seasonal variation of multiple sclerosis exacerbations in North Dakota. Arch Neurol 1989;46:1107-12. PMID 2775006
121: Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993;72:551-60.** PMID 7679952
122: Group CHAMPS. MRI predictors of early conversion to clinically definite multiple sclerosis in the CHAMPS placebo group. Neurology 2002;59:998-1005. PMID 12370452
123: Gulcher JR, Vartanian T, Stefansson K. Is multiple sclerosis an autoimmune disease. Clin Neurosci 1994;2:246-52. PMID 7749894
124: Haas J, Fritzsching B, Trubswetter P, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 2007;179:1322-30. PMID 17617625
125: Hamamcioglu K, Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007;13(4):459-70. PMID 17463069
126: Hecker M, Fitzner B, Jäger K, et al. Leukocyte telomere length in patients with multiple sclerosis and its association with clinical phenotypes. Mol Neurobiol 2021;58(6):2886-96. PMID 33547621
127: Hedstrom AK, Alfredsson L, Olsson T. Environmental factors and their interactions with risk genotypes in MS susceptibility. Curr Opin Neurol 2016;29(3):293-8. PMID 27035899
128: Hedstrom AK, Lima Bomfim I, Barcellos L, et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 2014;82(10):865-72. PMID 24500647
129: Henning DA, Huisinga JM, Lynch S, Fritz NE. Cognition and proprioception in persons with multiple sclerosis and healthy controls: nascent findings. Mult Scler Relat Disord 2022;68:104372. PMID 36544319
130: Herrera BM, Ramagopalan SV, Orton S, et al. Parental transmission of multiple sclerosis in a population-based Canadian cohort. Neurology 2007;69(12):1208-12. PMID 17596583
131: Hickey WF. The pathology of multiple sclerosis: a historical perspective. J Neuroimmunol 1999;98:37-44.** PMID 10426360
132: Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of multiple sclerosis. Mayo Clin Proc 1997;72:871-8.** PMID 9294536
133: Hug A, Korporal M, Schroder I, et al. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J Immunol 2003;171(1):432-7.** PMID 12817027
134: Hughes J, Jokubaitis V, Lugaresi A, et al. Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis. JAMA Neurol 2018;75(11):1407-15. PMID 30083762
135: Huitinga I, Erkut ZA, van Beurden D, Swaab DF. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann Neurol 2004;55:37-45. PMID 14705110
136: Iaffaldano P, Portaccio E, Lucisano G, et al. Multiple sclerosis progression and relapse activity in children. JAMA Neurol 2024;81(1):50-8. PMID 38010712
137: Ibrahim MZ, Reder AT. The mast cells of the multiple sclerosis brain. J Neuroimmunol 1996;70:131-8. PMID 8898721
138: Ifergan I, Kebir H, Bernard M, et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008;131:785-99. PMID 18156156
139: Ioannou M, Alissafi T, Lazaridis I, et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol 2012;188(3):1136-46. PMID 22210912
140: Ishizu T, Osoegawa M, Mei F, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128:988-1002. PMID 15743872
141: Ivanov, II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008;4:337-49. PMID 18854238
142: Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-43. PMID 9281381
143: Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther 2006;110(1):35-56. PMID 16229894
144: Jensen LT, Fugger L. Immune perturbation by the ileal microbiota in multiple sclerosis. Proc Natl Acad Sci U S A 2025;122(21):e2506777122. PMID 40388629
145: Jensen MA, Yanowitch RN, Reder AT, White DM, Arnason BG. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler 2010;16(1):30-8. PMID 20007427
146: John GR, Shankar SL, Shafit-Zagardo B, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nature Med 2002;8:1115-20.** PMID 12357247
147: Jurewicz A, Matysiak M, Raine CS, Selmaj K. Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007;68:283-7. PMID 17242333
148: Kampman MT, Steffensen LH. The role of vitamin D in multiple sclerosis. J Photochem Photobiol B 2010;101(2):137-41.** PMID 20471852
149: Kang JH, Sheu JJ, Kao S, Lin HC. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study. J Infect Dis 2011;204(2):188-92. PMID 21653524
150: Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002;123:144-59. PMID 11880159
151: Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in multiple sclerosis. Neurology 2003;61:238-40. PMID 12874407
152: Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010;9(7):681-8.** PMID 20621711
153: Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 2020;77(9):1132-40. PMID 32511687
154: Karaszewski JW, Reder AT, Anlar B, Kim WC, Arnason BG. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol 1991;30:42-7. PMID 1656847
155: Karaszewski JW, Reder AT, Maselli R, Brown M, Arnason BG. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol 1990;27:366-72.** PMID 2162144
156: Karni A, Abraham M, Monsonego A, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006;177:4196-202. PMID 16951385
157: Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis. A study of 31 patients. Ann Neurol 1993;33:18-27.** PMID 8494332
158: Khatibi E, Reder AT. The activating Zeta chain of the T cell receptor is increased on multiple sclerosis lymphocytes. Mult Scler 2008;14:P719, S241.
159: Kira J, Kanai T, Nishimura Y, et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996;40:569-74. PMID 8871575
160: Kira J, Yamasaki K, Horiuchi I, Ohyagi Y, Taniwaki T, Kawano Y. Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci 1999;166:53-7.** PMID 10465500
161: Kivisakk P, Tian W, Matusevicius D, Link H, Soderstrom M. Optic neuritis and cytokines. No relation to MRI abnormalities and oligoclonal bands. Neurology 1998;50:217-23. PMID 9443483
162: Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish multiple sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-9.** PMID 9667561
163: Kraus J, Kuehne KJ, Tofighi J, et al. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis. Acta Neurol Scand 2002;105:300-8. PMID 11939943
164: Kreiter D, Kalincik T, Hupperts R, et al. Effectiveness of disease-modifying treatment on spinal cord lesion formation in relapse-onset multiple sclerosis: an MSBase registry study. CNS Drugs 2024;38(11):921-30. PMID 39242483
165: Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-12.** PMID 12244078
166: Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 1975;51:110-36.** PMID 1114878
167: Kurtzke JF. Multiple sclerosis: changing times. Neuroepidemiology 1991;10:1-8.** PMID 2062411
168: Kurtzke JF, Beebe GW, Norman JE. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979;29:1228-35. PMID 573402
169: Kurtzke JF, Hyllested K, Heltberg A, Olsen A. Multiple sclerosis in the Faroe Islands: 5. The occurrence of the fourth epidemic as validation of transmission. Acta Neurol Scand 1993;88:161-73. PMID 8256551
170: Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013;80(6):548-52.** PMID 23365063
171: Lassmann H. The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008;18(4):563-76, ix.** PMID 19068402
172: Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210-8.** PMID 17388952
173: Lassmann H, Suchanek G, Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994;36:S42-6. PMID 8017888
174: Law M, Saindans AM, Ge Y, et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004;231:645-52. PMID 15163806
175: Lee MA, Smith S, Palace J, et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis. Brain 1999;122:1261-70. PMID 10388792
176: Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and blood-brain-barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007;33(1):86-98. PMID 17239011
177: Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001;58:57-60. PMID 11176937
178: Li J, Johansen C, Bronnum-Hansen H, Stenager E, Koch-Henriksen N, Olsen J. The risk of multiple sclerosis in bereaved parents: a nationwide cohort study in Denmark. Neurology 2004;62:726-9. PMID 15007121
179: Li Y, Chen Y, Yang L. Redefining multiple sclerosis with CAE-T cell therapy. Mol Ther 2025;S1525-0016(25)01045-7. PMID 41383015
180: Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998;4(1):12-5. PMID 9532586
181: Linker RA, Gaupp S, Holtmann B, et al. CNTF-deficiency deteriorates clinical course and histopathology in a murine model of experimental autoimmune encephalomyelitis: a neurotrophic factor as outcome determinator of neuroinflammation. Neurology 2001;56:A67.
182: Liu Y, Teige I, Birnir B, Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 2006;12:518-25. PMID 16633347
183: LoPresti P. HDAC6 in diseases of cognition and of neurons. Cells 2020;10(1):12. PMID 33374719
184: Lu CZ, Jensen MA, Arnason BG. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol 1993;46:123-8. PMID 7689582
185: Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011;76(6):540-8.** PMID 21300969
186: Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 1999;122:2279-95. PMID 10581222
187: Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.** PMID 10852536
188: Ludwin SK. The pathogenesis of multiple sclerosis: relating human pathology to experimental studies. J Neuropathol Exp Neurol 2006;65:305-18. PMID 16691112
189: Lyons PD, Blalock JE. Pre-opiomelanocortin gene expression and protein processing in rat mononuclear leukocytes. J Neuroimmunol 1997;78:47-56. PMID 9307227
190: Ma Y, Sannino D, Linden JR, et al. Epsilon toxin-producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege. J Clin Invest 2023;133(9):e163239.** PMID 36853799
191: Maggi P, Sati P, Nair G, et al. Paramagnetic rim lesions are specific to multiple sclerosis: an international multicenter 3T MRI study. Ann Neurol 2020;88(5):1034-42. PMID 32799417
192: Magliozzi R, Scalfari A, Pisani AI, et al. The CSF profile linked to cortical damage predicts multiple sclerosis activity. Ann Neurol 2020;88(3):562-73. PMID 32418239
193: Mahajan KR, Nakamura K, Cohen JA, Trapp BD, Ontaneda D. Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis. Ann Neurol 2020;88(1):81-92. PMID 32286701
194: Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and sera of patients with multiple sclerosis. J Neuroimmunol 1991;32:67-74. PMID 2002092
195: Maimone D, Reder AT. Soluble CD8 levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. Neurology 1991;41:851-4. PMID 1904563
196: Manavalan JS, Kim-Schulze S, Scotto L, et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ LT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004;16:1055-68. PMID 15226269
197: Manrique-Hoyos N, Jurgens T, Gronborg M, et al. Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann Neurol 2012;71(2):227-44.** PMID 22367995
198: Marmor M, Sheppard HW, Donnell D, et al. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001;27:472-81. PMID 11511825
199: Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races. Neurology 2006;66:1235-40. PMID 16636241
200: Martin R, Voskuhl R, Flerlage M, McFarlin DE, McFarland HF. Myelin basic protein-specific T cell responses in identical twins discordant or concordant for multiple sclerosis. Ann Neurol 1993;34:524-35. PMID 7692808
201: Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 2008;38:576-86. PMID 18200504
202: Masaki K, Sonobe Y, Ghadge G, et al. RNA-binding protein altered expression and mislocalization in MS. Neurol Neuroimmunol Neuroinflamm 2020;7(3):e704. PMID 32217641
203: Matarese G, Carrieri PB, Montella S, De Rosa V, La Cava A. Leptin as a metabolic link to multiple sclerosis. Nat Rev Neurol 2010;6(8):455-61. PMID 20606678
204: Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-22. PMID 8673485
205: Mattson DH, Roos RP, Arnason BG. Isoelectric focusing of IgG eluted from multiple sclerosis, subacute sclerosing panencephalitis and normal brains. Nature 1980;287:335-7.** PMID 7421992
206: Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003;61:1373-7. PMID 14638958
207: McAlpine D, Compston ND, Acheson E. Multiple sclerosis: a reappraisal. Edinburgh and London: Livingstone, 1972.
208: Meier DS, Weiner HL, Guttmann CR. MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. AJNR Am J Neuroradiol 2007;28:1956-63. PMID 17998417
209: Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006;59:880-92. PMID 16718690
210: Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nature Med 2007;13:1228-33.** PMID 17906634
211: Mian MF, Stampfli MR, Mossman KL, Ashkar AA. Cigarette smoke attenuation of poly I:C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFN-beta production. Mol Immunol 2009;46(5):821-9. PMID 18930547
212: Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 2019;366(6465):599-606.** PMID 31672891
213: Mitsdoerffer M, Schreiner B, Kieseier BC, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2005;159:155-64. PMID 15652415
214: Mold JE, Michaelsson J, Burt TD, et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 2008;322:1562-5. PMID 19056990
215: Moll NM, Cossoy MB, Fisher E, et al. Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009;66(1):44-53. PMID 19139298
216: Monson NL, Brezinschek HP, Brezinschek RI, et al. Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol 2004;158:170-81. PMID 15589051
217: Muller DM, Pender MP, Greer JM. Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. J Neuroimmunol 2005;160:162-9. PMID 15710469
218: Mumford CJ, Wood NW, Kellar-Wood H, Thorpe JW, Miller DH, Compston DA. The British Isles survey of multiple sclerosis in twins. Neurology 1994;44:11-5. PMID 8290043
219: Munger KL, Alvo J, Hongell K, Soilu-Hanninen M, Surcel HM, Ascherio A. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish Maternity Cohort. JAMA Neurol 2016;73(5):515-9. PMID 26953778
220: Munger KL, Köchert K, Simon KC, et al. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann Clin Transl Neurol 2014;1(8):605-17. PMID 25285313
221: Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-5. PMID 14718698
222: Murphy CB, Hashimoto SA, Grach D, Thiessen BA. Clinical exacerbation of multiple sclerosis following radiotherapy. Arch Neurol 2003;60:273-5. PMID 12580715
223: Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979-86.** PMID 11757963
224: Nguyen K, Olcer M, Howlett-Prieto Q, et al. Prolonged interferon-stimulated gene and protein signatures in multiple sclerosis induced by PEGylated IFN-β-1a compared to non-PEGylated IFN-β-1a. J Interferon Cytokine Res 2023;43(3):108-20. PMID 36867172
225: Nielsen AS, Kinkel RP, Madigan N, Tinelli E, Benner T, Mainero C. Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in multiple sclerosis. Neurology 2013;81(7):641-9. PMID 23864311
226: Nisipeanu P, Korczyn AD. Psychological stress as risk factor for exacerbations in multiple sclerosis. Neurology 1993;43:1311-2.** PMID 8327130
227: Norgaard M, Nielsen RB, Jacobsen JB, et al. Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol 2011;174(8):945-8. PMID 21920946
228: Nouri-Shirazi M, Guinet E. Exposure to nicotine adversely affects the dendritic cell system and compromises host response to vaccination. J Immunol 2012;188(5):2359-70. PMID 22279108
229: Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006;5:932-6. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5:932-6. PMID 17052660
230: Pagani E, Rocca MA, Gallo A, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 2005;26:341-6. PMID 15709132
231: Page WF, Kurzke JF, Murphy FM, Norman JE. Epidemiology of multiple sclerosis in U.S. veterans: V. Ancestry and the risk of multiple sclerosis. Ann Neurol 1993;33:632-9.** PMID 8498844
232: Paiva RS, Lino AC, Bergman ML, et al. Recent thymic emigrants are the preferential precursors of regulatory T cells differentiated in the periphery. Proc Natl Acad Sci U S A 2013;110(16):6494-9. PMID 23576744
233: Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm 2015;2(6):e158. PMID 26468472
234: Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36:S25-S8. PMID 8017885
235: Panitch HS, Bever CT, Katz E, Johnson KP. Upper respiratory tract infections trigger attacks of multiple sclerosis in patients treated with interferon. J Neuroimmunol 1991;(Suppl 1):125.**
236: Pantano P, Caramia F, Piattella MC, et al. From new enhancing lesions to “black holes” in patients with clinically isolated syndrome suggestive of multiple sclerosis. J Neurol 2001;248:302.
237: Papadopoulos D, Magliozzi R, Bandiera S, et al. Accelerated cellular senescence in progressive multiple sclerosis: a histopathological study. Ann Neurol 2025;97(6):1074-87. PMID 39891488
238: Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404. PMID 11274650
239: Parry A, Corkill R, Blamire AM, et al. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003;250:171-8. PMID 12574947
240: Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006;129(Pt 12):3165-72.** PMID 16921173
241: Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400. PMID 11558796
242: Petrova N, Nutma E, Carassiti D, et al. Synaptic loss in multiple sclerosis spinal cord. Ann Neurol 2020;88(3):619-25. PMID 32608018
243: Piyasirisilp S, Schmeckpeper BJ, Chandanayingyong D, Hemachudha T, Griffin DE. Association of HLA and T cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis. Ann Neurol 1999;45:595-600.** PMID 10319881
244: Ponsonby AL, van der Mei I, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 2005;293:463-9. PMID 15671431
245: Portaccio E, Bellinvia A, Fonderico M, et al. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain 2022;145(8):2796-805. PMID 35325059
246: Poser CM. Pathogenesis of multiple sclerosis. A critical reappraisal. Acta Neuropathol 1986;71:1-10. PMID 3535354
247: Prat A, Biernacki K, Becher B, Antel JP. B7 expression and antigen presentation by human brain endothelial cells: requirement for proinflammatory cytokines. J Neuropathol Exp Neurol 2000a;59:129-36. PMID 10749102
248: Prat A, Pelletier D, Duquette P, Arnold DL, Antel JP. Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann Neurol 2000b;47:234-7. PMID 10665495
249: Prineas JW. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979;203:1123-5.** PMID 424741
250: Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993;33:137-51.** PMID 8434875
251: Probstel AK, Zhou X, Baumann R, et al. Gut microbiota–specific IgA+ B cells traffic to the CNS in active multiple sclerosis. Sci Immunol 2020;5(53):1-13. PMID 33219152
252: Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182-91.** PMID 12127652
253: Quinn MP, Kremenchutzky M, Menon RS. Venocentric lesions: An MRI marker of multiple sclerosis. Front Neurol 2013;4:98.** PMID 23885252
254: Quintana FJ. The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. Immunology 2013;138(3):183-9. PMID 23190340
255: Ragheb S. Multiple sclerosis: genetic background versus environment. Ann Neurol 1993;34:509-10. PMID 7692806
256: Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011;17(7):819-29. PMID 21372118
257: Raine CS. Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 1991;17:265-74.** PMID 1944803
258: Ramagopalan SV, Yee IM, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations from interracial matings. Neurology 2009;73(8):602-5. PMID 19515994
259: Raper D, Louveau A, Kipnis J. How do meningeal lymphatic vessels drain the CNS? Trends Neurosci 2016;39(9):581-6. PMID 27460561
260: Rapp NS, Gilroy J, Lerner AM. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995;4:415-8. PMID 8534384
261: Reder AT. Regulation of production of adrenocorticotropin-like proteins in human mononuclear cells. Immunology 1992;77:436-42. PMID 1335962
262: Reder AT. Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models. J Clin Invest 2023;133(9):e169643. PMID 37115699
263: Reder AT, Antel JP, Oger JJ, McFarland TA, Rosenkoetter M, Arnason BG. Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann Neurol 1984;16(2):242-9. PMID 6236742
264: Reder AT, Arnason BG. Immunology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL, Koetsier JC, editors. Handbook of clinical neurology: demyelinating diseases. Amsterdam: North Holland Publishing, 1985:337-95.**
265: Reder AT, Arnason BG, Maimone D, Rohwer-Nutter D. The function of the CD2 protein is abnormal in multiple sclerosis. J Autoimmun 1991;4(3):479-91. PMID 1680333
266: Reder AT, Goel A, Garcia T, Feng X. Alternative splicing of genes is excessive in multiple sclerosis and not linked to gene expression levels: dysregulation is corrected by IFN-beta. J Interferon Cytokine Res 2024;44(8):355-71.** PMID 38695855
267: Reder AT, Lowy MT, Meltzer HY, Antel JP. Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology 1987;37:849-53. PMID 3033547
268: Reder AT, Makowiec RL, Lowy M. Adrenal size is increased in multiple sclerosis. Arch Neurol 1994c;51:151-4. PMID 8304840
269: Reder AT, Thapar M, Jensen M. A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology 1994a;44:2289-94. PMID 7991114
270: Reder AT, Thapar M, Sapugay AM, Jensen MA. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol 1994b;54(1-2):117-27. PMID 7523442
271: Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in multiple sclerosis. J Neuroimmunol 2006;180(1-2):50-62. PMID 16934337
272: Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999;122:2047-56. PMID 10545390
273: Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a “paravascular” fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 1985;326:47-63. PMID 3971148
274: Rieckmann P, Albrecht M, Kitze B, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-6.** PMID 8058164
275: Rodriguez Cruz PM, Matthews L, Boggild M, et al. Time- and region-specific season of birth effects in multiple sclerosis in the United Kingdom. JAMA Neurol 2016;73(8):954-60. PMID 27366989
276: Rosenbluth J, Schiff R, Liang WL, Dou WK, Moon D. Antibody-mediated central nervous system demyelination: focal spinal cord lesions induced by implantation of an IgM antigalactocerebroside-secreting hybridoma. J Neurocytol 1999;28:397-416.** PMID 10739579
277: Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998;44:980-3. PMID 9851447
278: Sadovnick AD, Armstrong H, Rice GP, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993;33:281-5. PMID 8498811
279: Sadovnick AD, Duquette P, Herrera B, Yee IM, Ebers GC. A timing-of-birth effect on multiple sclerosis clinical phenotype. Neurology 2007;69:60-2. PMID 17606881
280: Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4. PMID 1579256
281: Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting multiple sclerosis. Neurology 2000;55:61-5. PMID 10891907
282: Sakai S, Takaishi H, Matsuzaki K, et al. 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab 2009;27(6):643-52. PMID 19449179
283: Sandberg-Wollheim M, Kornmann G, Bischof D, et al. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings. Mult Scler 2011;17(4):431-40.** PMID 21486902
284: Sarkkinen J, Yohannes DA, Kreivi N, et al. Altered immune landscape of cervical lymph nodes reveals Epstein-Barr virus signature in multiple sclerosis. Sci Immunol 2025;10(104):eadl3604.** PMID 39982975
285: Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005;62:569-73. PMID 15824254
286: Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133(Pt 7):1914-29.** PMID 20534650
287: Schmidt S. Candidate autoantigens in multiple sclerosis. Mult Scler 1998;5:147-60.** PMID 10408714
288: Schutzer SE, Angel TE, Liu T, et al. Gray matter is targeted in first-attack multiple sclerosis. PLoS One 2013;8(9):e66117. PMID 24039694
289: Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-912. PMID 17984305
290: Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-74.** PMID 15193029
291: Sharief MK. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. J Neuroimmunol 2000;109:236-43. PMID 10996226
292: Shi K, Li H, Chang T, et al. Bone marrow hematopoiesis drives multiple sclerosis progression. Cell 2022;185(13):2234-47.e17. PMID 35709748
293: Sibley WA. Risk factors in multiple sclerosis: implications for pathogenesis. In: Crescenzi GS, editor. A multidisciplinary approach to myelin diseases. New York: Plenum Publishing Corp, 1988:227-32.
294: Sibley WA. Physical trauma and multiple sclerosis. Neurology 1993;43:1871-4.** PMID 8413939
295: Sibley WA. The effect of virus-like infections on the course of multiple sclerosis. In: Hommes OR, Wekerle H, Clanet M, editors. Genes and Viruses in multiple sclerosis. Elsevier Science BV, 2001:89-95.**
296: Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-5.** PMID 2860501
297: Simats A, Zhang S, Messerer D, et al. Innate immune memory after brain injury drives inflammatory cardiac dysfunction. Cell 2024;187(17):4637-55.e26. PMID 39043180
298: Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing multiple sclerosis: MSCRG trial of interferon beta-1a. Multiple sclerosis Collaborative Research Group. Neurology 2000;55:185-92. PMID 10908888
299: Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther 2018;7(1):59-85. PMID 29243029
300: Siva A, Radhakrishnan K, Kurland LT, O'Brien PC, Swanson JW, Rodriguez M. Trauma and multiple sclerosis: a population-based cohort study from Olmsted County, Minnesota. Neurology 1993;43:1878-82.** PMID 8413941
301: Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998;50:708-14. PMID 9521261
302: Sotirchos ES, Gonzalez Caldito N, Filippatou A, et al. Progressive multiple sclerosis Is associated with faster and specific retinal layer atrophy. Ann Neurol 2020;87(6):885-96. PMID 32285484
303: Spadaro M, Amendolea MA, Mazzucconi MG, et al. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler 1999;5:121-5. PMID 10335521
304: Spelman T, Gray O, Trojano M, et al. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol 2014;76(6):880-90. PMID 25283272
305: Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012;367(2):115-23. PMID 22784115
306: Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006;129(Pt 5):1293-305. PMID 16513684
307: Szuchet S, Nielsen LL, Domowicz MS, Austin JR 2nd, Arvanitis DL. CNS myelin sheath is stochastically built by homotypic fusion of myelin membranes within the bounds of an oligodendrocyte process. J Struct Biol 2015;190(1):56-72. PMID 25682762
308: Szuchet S, Nielsen JA, Lovas G, et al. The genetic signature of perineuronal oligodendrocytes reveals their unique phenotype. Eur J Neurosci 2011;34(12):1906-22. PMID 22132705
309: Taheri S, Rosenberg GA, Ford C. Quantification of blood-to-brain transfer rate in multiple sclerosis. Mult Scler Relat Disord 2013;2(2):124-32. PMID 25877634
310: Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004;127:1917-27. PMID 15229129
311: Tan IL, van Schijndel RA, Pouwels PJ, et al. MR venography of multiple sclerosis. AJNR Am J Neuroradiol 2000;21:1039-42. PMID 10871010
312: Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006;176(11):7119-29.** PMID 16709875
313: Then Bergh F, Kümpfelt T, Trenkwalder C, Rupprecht R, Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of multiple sclerosis. Neurology 1999;53:772-7. PMID 10489039
314: Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005;64:1001-7. PMID 15781816
315: Torkildsen O, Wergeland S, Bakke S, et al. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012;69(8):1044-51. PMID 22507886
316: Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.** PMID 9445407
317: Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009;8(3):280-91.** PMID 19233038
318: Trapp BD, Vignos M, Dudman J, et al. Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol 2018;17(10):870-84. PMID 30143361
319: Traugott U, Scheinberg LC, Raine CS. On the presence of Ia-positive endothelial cells and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation. J Neuroimmunol 1985;8:1-14.** PMID 3882754
320: Trotter JL, Kelly GC, van der Veen RC. Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. J Neuroimmunol 1991;33:29-36. PMID 2056069
321: Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007;8:355-67. PMID 17453016
322: Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-55. PMID 18156204
323: Tzartos JS, Khan G, Vossenkamper A, et al. Association of innate immune activation with latent Epstein-Barr virus in active multiple sclerosis lesions. Neurology 2012;78(1):15-23. PMID 22156987
324: van den Bosch AMR, Hümmert S, Steyer A, et al. Ultrastructural axon-myelin unit alterations in multiple sclerosis correlate with inflammation. Ann Neurol 2023;93(4):856-70. PMID 36565265
325: van der Meer JW, Netea MG. A salty taste to autoimmunity. N Engl J Med 2013;368(26):2520-1. PMID 23802520
326: van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype and risk of multiple sclerosis: case-control study. BMJ 2003;327:316-20. PMID 12907484
327: van Langelaar J, Rijvers L, Janssen M, et al. Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis. Ann Neurol 2019;86(2):264-78. PMID 31136008
328: van Nierop GP, van Luijn MM, Michels SS, et al. Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathol 2017;134(3):383-401. PMID 28624961
329: Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009;206:43-9. PMID 19114668
330: Venken K, Hellings N, Broekmans T, et al. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol 2008;180:6411-20. PMID 18424765
331: Vercellino M, Votta B, Condello C, et al. Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study. J Neuroimmunol 2008;199:133-41. PMID 18539342
332: Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007;256 Suppl 1:S5-13.** PMID 17346747
333: von Geldern G, Mowry EM. The influence of nutritional factors on the prognosis of multiple sclerosis. Nat Rev Neurol 2012;8(12):678-89. PMID 23026980
334: Wahls TL, Titcomb TJ, Bisht B, et al. Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: the WAVES randomized parallel-arm clinical trial. Mult Scler J Exp Transl Clin 2021;7(3):20552173211035399. PMID 34377527
335: Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019;92(10):e1029-40. Erratum in: Neurology 2019;93(15):688. PMID 30770430
336: Wallrapp A, Chiu IM. Neuroimmune interactions in the intestine. Annu Rev Immunol 2024;42(1):489-519. PMID 38941607
337: Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001;50:349-57.** PMID 11558791
338: Warren KG, Catz I, Johnson E, Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 1994;35:280-9. PMID 7510098
339: Waubant E, Mowry EM, Krupp L, et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 2011;76(23):1989-95. PMID 21646624
340: Waxman SG. Ion channels and neuronal dysfunction in multiple sclerosis. Arch Neurol 2002;59:1377-80. PMID 12223023
341: Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007;4:647-53. PMID 17920545
342: Weilbach FX, Toyka KV. Does Down's syndrome protect against multiple sclerosis. Eur Neurol 2002;47:52-5.** PMID 11803193
343: Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-80. PMID 11506399
344: Whelan HT, Pledger WJ, Maciunas RJ, Galloway RL Jr, Whetsell WO Jr, Moses HL. Growth factors in the tumorigenicity of a brain tumor cell line. Pediatr Neurol 1989;5:271-9. PMID 2803384
345: Whitaker JN, Kachelhofer RD, Bradley EL, et al. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 1995;38:625-32.** PMID 7574459
346: Wu C, Yosef N, Thalhamer T, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013;496(7446):513-7. PMID 23467085
347: Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. Update on the epidemiology of multiple sclerosis. Mayo Clin Proc 1989;64:808-17. PMID 2671520
348: Yamaguchi KD, Ruderman DL, Croze E, et al. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting multiple sclerosis mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol 2008;195(1-2):116-20.** PMID 18279974
349: Yea C, Tellier R, Chong P, et al. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology 2013;81(16):1392-9. PMID 24014504
350: York NR, Mendoza JP, Ortega SB, et al. Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J Autoimmun 2010;35(1):33-44. PMID 20172692
351: Yoshimura S, Isobe N, Yonekawa T, et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One 2012;7(11):e48592. PMID 23152786
352: Ysrraelit MC, Gaitan MI, Lopez AS, Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 2008;71:1948-54.** PMID 19064876
353: Zastepa E, Fitz-Gerald L, Hallett M, et al. Naive CD4 T-cell activation identifies multiple sclerosis patients having rapid transition to progressive multiple sclerosis. Neurology 2014;82(8):681-90. PMID 24453076
354: Zeis T, Schaeren-Wiemers N. Lame ducks or fierce creatures. The role of oligodendrocytes in multiple sclerosis. J Mol Neurosci 2008;35:91-100. PMID 18278568
355: Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology 2008;70(13 Pt 2):1092-7.** PMID 18003938
356: Zipp F, Krammer PH, Weller M. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 1999;20:550-4. PMID 10562705
357: Zwemmer JN, Bot JC, Jelles B, Barkhof F, Polman CH. At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only. Mult Scler 2008;14:428-30. PMID 18208890

Patient Profile

Age range of presentation: 6 to 64 years
Sex preponderance: female>male, >2:1 and ratio is increasing for the past 50 years, now up to 3.2:1 in Canada (Orton et al 2006)
Heredity: heredity may be a factor
Population groups selectively affected: Caucasians

Northern Europeans
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Multiple sclerosis: G35
ICD-11: Multiple sclerosis: 8A40
OMIM: Multiple sclerosis: #126200

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Multiple sclerosis: neuroimmunology

Associated Disorders

Optic neuritis
Pars planitis (peripheral uveitis)
Seizure disorder
Transverse myelitis
Trigeminal neuralgia
- Uveitis

Also Relevant

Fatigue in multiple sclerosis
Intravenous immune globulin
Multiple sclerosis: neurobehavioral aspects
Multiple sclerosis: presentation and course
Sleep and multiple sclerosis

Multiple sclerosis: neuroimmunology …

Multiple sclerosis: neuroimmunology

Cite this article

Introduction

Overview

Key points

Etiology

Pathogenesis

Epidemiology

Media

References

Contributors

Author

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Upadacitinib

Guillain-Barre syndrome in children

Efgartigimod alfa-fcab

Efgartigimod alfa and hyaluronidase-qvfc

Ofatumumab

Neuropathies associated with cryoglobulinemia

Rheumatoid arthritis: neurologic manifestations

Primary CNS angiitis

Multiple sclerosis: neuroimmunology

Cite this article

Introduction

Overview

Key points

Etiology

Pathogenesis

Epidemiology

Media

References

Contributors

Author

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Upadacitinib

Guillain-Barre syndrome in children

Efgartigimod alfa-fcab

Efgartigimod alfa and hyaluronidase-qvfc

Ofatumumab

Neuropathies associated with cryoglobulinemia

Rheumatoid arthritis: neurologic manifestations

Primary CNS angiitis

This is an article preview.
Start a Free Account
to access the full version.